2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy

The Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC)

Authors/Task Force members: Perry M. Elliott* (Chairperson) (UK), Aris Anastasakis (Greece), Michael A. Borger (Germany), Martin Borggrefe (Germany), Franco Cecchi (Italy), Philippe Charron (France), Albert Alain Hagege (France), Antoine Lafont (France), Giuseppe Limongelli (Italy), Heiko Mahrholdt (Germany), William J. McKenna (UK), Jens Mogensen (Denmark), Petros Nihoyannopoulos (UK), Stefano Nistri (Italy), Petronella G. Pieper (Netherlands), Burkert Pieske (Austria), Claudio Raperazzi (Italy), Frans H. Rutten (Netherlands), Christoph Tillmanns (Germany), Hugh Watkins (UK).

Additional Contributor: Constantinos O’Mahony (UK).

ESC Committee for Practice Guidelines (CPG): Jose Luis Zamorano (Chairperson) (Spain), Stephan Achenbach (Germany), Helmut Baumgartner (Greece), Jeroen J. Bax (Netherlands), Héctor Bueno (Spain), Veronica Dean (France), Christi Deaton (UK), Cetin Erol (Turkey), Robert Fagard (Belgium), Roberto Ferrari (Italy), David Hasdai (Israel), Arno W. Hoes (Netherlands), Paulus Kirchhof (Germany/UK), Juhan Knuuti (Finland), Philippe Kolh (Belgium), Patrizio Lancetti (Belgium), Ales Linhart (Czech Republic), Petros Nihoyannopoulos (UK), Massimo F. Piepoli (Italy), Piotr Ponikowski (Poland), Per Anton Sirnes (Norway), Juan Luis Tamargo (Spain), Michal Tendera (Poland), Adam Torbicki (Poland), William Wijns (Belgium), Stephan Windecker (Switzerland).

Document Reviewers: David Hasdai (Israel) (CPG Review Coordinator), Piotr Ponikowski (Poland) (CPG Review Coordinator), Stephan Achenbach (Germany), Fernando Alfonso (Spain), Cristina Basso (Italy), Nuno Miguel Cardim (Portugal), Juan Ramón Gimeno (Spain), Stephane Heymans (Netherlands), Per Johan Holm (Sweden), Andre Keren

The content of these European Society of Cardiology (ESC) Guidelines has been published for personal and educational use only. No commercial use is authorized. No part of the ESC Guidelines may be translated or reproduced in any form without written permission from the ESC. Permission can be obtained upon submission of a written request to Oxford University Press, the publisher of the European Heart Journal and the party authorized to handle such permissions on behalf of the ESC.

Disclaimer: The ESC Guidelines represent the views of the ESC and were produced after careful consideration of the scientific and medical knowledge and the evidence available at the time of their drafting. The ESC is not responsible in the event of any contradiction, discrepancy and/or ambiguity between the ESC Guidelines and any other official recommendations or guidelines issued by the relevant public health authorities, in particular in relationship to good use of healthcare or therapeutic strategies. Health professionals are encouraged to take the ESC Guidelines fully into account when exercising their clinical judgment, as well as in the determination and the implementation of preventive, diagnostic or therapeutic medical strategies. However, the ESC Guidelines do not override, in any way whatsoever, the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient’s health condition and in consultation with that patient and, where appropriate and/or necessary, the patient’s caregiver. Nor do the ESC Guidelines exempt health professionals from taking careful and full consideration of the relevant official updated recommendations or guidelines issued by the competent public health authorities in order to manage each patient’s case in light of the scientifically accepted data pursuant to their respective ethical and professional obligations. It is also the health professional’s responsibility to verify the applicable rules and regulations relating to drugs and medical devices at the time of prescription.

National Cardiac Societies document reviewers: listed in Appendix 1

©The European Society of Cardiology 2014. All rights reserved. For permissions please email: journals.permissions@oup.com.
(Israel), Paulus Kirchhof (Germany/UK), Philippe Kolh (Belgium), Christos Lionis (Greece), Claudio Muneretto (Italy), Silvia Priori (Italy), Maria Jesus Salvador (Spain), Christian Wolpert (Germany), Jose Luis Zamorano (Spain).

The disclosure forms of the authors and reviewers are available on the ESC website www.escardio.org/guidelines

Online publish-ahead-of-print 29 August 2014

Table of Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Preamble</td>
<td>2736</td>
</tr>
<tr>
<td>2. Introduction</td>
<td>2737</td>
</tr>
<tr>
<td>2.1 Definition</td>
<td>2737</td>
</tr>
<tr>
<td>2.2 Scope of Guidelines</td>
<td>2737</td>
</tr>
<tr>
<td>3. Epidemiology</td>
<td>2738</td>
</tr>
<tr>
<td>4. Aetiology</td>
<td>2738</td>
</tr>
<tr>
<td>4.1 Sarcomere protein gene mutations</td>
<td>2738</td>
</tr>
<tr>
<td>4.2 Metabolic disorders</td>
<td>2738</td>
</tr>
<tr>
<td>4.3 Mitochondrial cardiomyopathies</td>
<td>2738</td>
</tr>
<tr>
<td>4.4 Neuromuscular disease</td>
<td>2738</td>
</tr>
<tr>
<td>4.5 Malformation syndromes</td>
<td>2738</td>
</tr>
<tr>
<td>4.6 Infiltrative disease/inflammation</td>
<td>2738</td>
</tr>
<tr>
<td>4.7 Endocrine disorders</td>
<td>2738</td>
</tr>
<tr>
<td>4.8 Drugs</td>
<td>2739</td>
</tr>
<tr>
<td>5. Diagnosis</td>
<td>2739</td>
</tr>
<tr>
<td>5.1 Diagnostic criteria</td>
<td>2739</td>
</tr>
<tr>
<td>5.1.1 Adults</td>
<td>2739</td>
</tr>
<tr>
<td>5.1.2 Children</td>
<td>2739</td>
</tr>
<tr>
<td>5.1.3 Relatives</td>
<td>2740</td>
</tr>
<tr>
<td>5.2 History and physical examination</td>
<td>2740</td>
</tr>
<tr>
<td>5.3 Resting and ambulatory electrocardiography</td>
<td>2742</td>
</tr>
<tr>
<td>5.4 Echocardiography</td>
<td>2742</td>
</tr>
<tr>
<td>5.4.1 Assessment of left ventricular wall thickness</td>
<td>2742</td>
</tr>
<tr>
<td>5.4.2 Associated abnormalities of the mitral valve and left ventricular outflow tract</td>
<td>2742</td>
</tr>
<tr>
<td>5.4.3 Assessment of latent obstruction</td>
<td>2743</td>
</tr>
<tr>
<td>5.4.4 Left atrial enlargement</td>
<td>2743</td>
</tr>
<tr>
<td>5.4.5 Assessment of diastolic function</td>
<td>2744</td>
</tr>
<tr>
<td>5.4.6 Systolic function</td>
<td>2744</td>
</tr>
<tr>
<td>5.4.7 Value of echocardiography in differential diagnosis</td>
<td>2744</td>
</tr>
<tr>
<td>5.4.8 Contrast echocardiography</td>
<td>2744</td>
</tr>
<tr>
<td>5.4.9 Transoesophageal echocardiography</td>
<td>2744</td>
</tr>
<tr>
<td>5.5 Cardiovascular magnetic resonance imaging</td>
<td>2745</td>
</tr>
<tr>
<td>5.5.1 Assessment of ventricular morphology and function</td>
<td>2745</td>
</tr>
<tr>
<td>5.5.2 Myocardial fibrosis</td>
<td>2746</td>
</tr>
<tr>
<td>5.5.3 Late Gadolinium Enhancement and Prognosis</td>
<td>2746</td>
</tr>
<tr>
<td>5.5.4 Differential diagnosis</td>
<td>2746</td>
</tr>
<tr>
<td>5.6 Nuclear imaging and computerized tomography</td>
<td>2747</td>
</tr>
<tr>
<td>5.7 Endomyocardial biopsy</td>
<td>2747</td>
</tr>
<tr>
<td>5.8 Laboratory tests</td>
<td>2747</td>
</tr>
<tr>
<td>6. Genetic testing and family screening</td>
<td>2747</td>
</tr>
<tr>
<td>6.1 Counselling in probands</td>
<td>2748</td>
</tr>
<tr>
<td>6.2 Methods for molecular genetic screening in probands</td>
<td>2748</td>
</tr>
<tr>
<td>6.3 Indications for genetic testing in probands</td>
<td>2748</td>
</tr>
<tr>
<td>6.4 Genetic and clinical screening</td>
<td>2749</td>
</tr>
<tr>
<td>6.4.1 Families with definite disease causing genetic mutations</td>
<td>2749</td>
</tr>
<tr>
<td>6.4.2 Families without definite disease causing genetic mutations</td>
<td>2749</td>
</tr>
<tr>
<td>6.5 Clinical and genetic screening</td>
<td>2750</td>
</tr>
<tr>
<td>6.6 Follow-up of mutation carriers without a phenotype</td>
<td>2751</td>
</tr>
<tr>
<td>6.7 Pre-implantation and pre-natal genetic testing</td>
<td>2751</td>
</tr>
<tr>
<td>7. Delivery of care</td>
<td>2751</td>
</tr>
<tr>
<td>7.1 Education and training</td>
<td>2752</td>
</tr>
<tr>
<td>8. Assessment of symptoms</td>
<td>2752</td>
</tr>
<tr>
<td>8.1 Chest pain</td>
<td>2752</td>
</tr>
<tr>
<td>8.2 Heart failure</td>
<td>2752</td>
</tr>
<tr>
<td>8.2.1 Invasive pressure studies</td>
<td>2753</td>
</tr>
<tr>
<td>8.2.2 Cardiopulmonary exercise testing</td>
<td>2753</td>
</tr>
<tr>
<td>8.3 Syncope</td>
<td>2753</td>
</tr>
<tr>
<td>8.4 Palpitations</td>
<td>2754</td>
</tr>
<tr>
<td>8.5 Role of electrophysiological testing</td>
<td>2754</td>
</tr>
<tr>
<td>9. Management of symptoms and complications</td>
<td>2755</td>
</tr>
<tr>
<td>9.1 Left ventricular outflow tract obstruction</td>
<td>2755</td>
</tr>
<tr>
<td>9.1.1 General measures</td>
<td>2755</td>
</tr>
<tr>
<td>9.1.2 Drug therapy</td>
<td>2755</td>
</tr>
<tr>
<td>9.1.3 Invasive treatment of left ventricular outflow tract obstruction</td>
<td>2756</td>
</tr>
<tr>
<td>9.1.3.1 Surgery</td>
<td>2756</td>
</tr>
<tr>
<td>9.1.3.2 Septal alcohol ablation</td>
<td>2756</td>
</tr>
<tr>
<td>9.1.3.3 Surgery vs. alcohol ablation</td>
<td>2757</td>
</tr>
<tr>
<td>9.1.3.4 Minimum activity requirements</td>
<td>2757</td>
</tr>
<tr>
<td>9.1.3.5 Dual chamber pacing</td>
<td>2758</td>
</tr>
<tr>
<td>9.2 Left ventricular mid-cavity obstruction and apical aneurysms</td>
<td>2759</td>
</tr>
<tr>
<td>9.3 Management of symptoms in patients without left ventricular outflow tract obstruction</td>
<td>2759</td>
</tr>
<tr>
<td>9.3.1 Heart failure</td>
<td>2759</td>
</tr>
<tr>
<td>9.3.1.1 Drug therapy</td>
<td>2759</td>
</tr>
<tr>
<td>9.3.1.2 Cardiac resynchronization therapy</td>
<td>2760</td>
</tr>
<tr>
<td>9.3.1.3 Cardiac transplantation</td>
<td>2760</td>
</tr>
<tr>
<td>9.3.1.4 Left ventricular assist devices</td>
<td>2760</td>
</tr>
<tr>
<td>9.3.2 Angina</td>
<td>2760</td>
</tr>
</tbody>
</table>
1. Preamble

Guidelines summarize and evaluate all available evidence at the time of the writing process, on a particular issue with the aim of assisting health professionals in selecting the best management strategies for an individual patient, with a given condition, taking into account the impact on outcome, as well as the risk-benefit-ratio of particular diagnostic or therapeutic means. Guidelines and recommendations should help the health professionals to make decisions in their daily practice. However, the final decisions concerning an individual patient must be made by the responsible health professional(s) in consultation with the patient and caregiver as appropriate.

A great number of Guidelines have been issued in recent years by the European Society of Cardiology (ESC) as well as by other societies and organisations. Because of the impact on clinical practice, quality criteria for the development of guidelines have been established in order to make all decisions transparent to the user. The recommendations for formulating and issuing ESC Guidelines can be found on the ESC website (http://www.escardio.org/guidelines-surveys/esc-guidelines/about/Pages/rules-writing.aspx). ESC Guidelines represent the official position of the ESC on a given topic and are regularly updated.

Members of this Task Force were selected by the ESC to represent professionals involved with the medical care of patients with this pathology. Selected experts in the field undertook a comprehensive review of the published evidence for management (including diagnosis, treatment, prevention and rehabilitation) of a given condition according to ESC Committee for Practice Guidelines (CPG) policy. A critical evaluation of diagnostic and therapeutic procedures was performed including assessment of the risk-benefit-ratio. Estimates of expected health outcomes for larger populations were included, where data exist. The level of evidence and the strength of recommendation of particular management options were weighed and graded according to predefined scales, as outlined in Tables 1 and 2.

The experts of the writing and reviewing panels filled in declarations of interest forms which might be perceived as real or potential sources of conflicts of interest. These forms were compiled into one file and can be found on the ESC website (http://www.escardio.org/guidelines). Any changes in declarations of interest that arise during the writing period must be notified to the ESC and updated. The Task Force received its entire financial support from the ESC without any involvement from healthcare industry.

The ESC CPG supervises and coordinates the preparation of new Guidelines produced by Task Forces, expert groups or consensus panels. The Committee is also responsible for the endorsement process of these Guidelines. The ESC Guidelines undergo extensive review by the CPG and external experts. After appropriate revisions it is approved by all the experts involved in the Task Force. The finalized document is approved by the CPG for publication in the European Heart Journal. It was developed after careful consideration of the scientific and medical knowledge and the evidence available at the time of their dating.

The task of developing ESC Guidelines covers not only the integration of the most recent research, but also the creation of educational tools and implementation programmes for the recommendations. To implement the guidelines, condensed pocket guidelines versions, summary slides, booklets with essential messages, summary cards for non-specialists, electronic version for digital applications (smartphones etc) are produced. These versions are abridged and, thus, if needed, one should always refer to the full text version which is freely available on the ESC website. The National Societies of the ESC are encouraged to endorse, translate and implement the ESC Guidelines. Implementation programmes are needed because it has been shown that the outcome of disease may be favourably influenced by the thorough application of clinical recommendations.

Surveys and registries are needed to verify that real-life daily practice is in keeping with what is recommended in the guidelines, thus completing the loop between clinical research, writing of guidelines, disseminating them and implementing them into clinical practice.

Health professionals are encouraged to take the ESC Guidelines fully into account when exercising their clinical judgment as well as in the determination and the implementation of preventive,
diagnostic or therapeutic medical strategies. However, the ESC Guidelines do not override in any way whatsoever the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient’s health condition and in consultation with that patient and the patient’s caregiver where appropriate and/or necessary. It is also the health professional’s responsibility to verify the rules and regulations applicable to drugs and devices at the time of prescription.

2. Introduction

2.1 Definition

Cardiomyopathies are defined by structural and functional abnormalities of the ventricular myocardium that are unexplained by flow-limiting coronary artery disease or abnormal loading conditions.1 Historically, this group of disorders has been subdivided into primary disease, in which the heart is the only involved organ, and secondary forms where the cardiomyopathy is a manifestation of a systemic disorder. These Guidelines adopt a classification system proposed in a recent ESC position statement, in which cardiomyopathies are defined by specific morphological and functional criteria and then grouped into familial/genetic and non-familial/non-genetic subtypes, irrespective of the presence of extra-cardiac disease.1

Hypertrophic cardiomyopathy (HCM) is defined by the presence of increased left ventricular (LV) wall thickness that is not solely explained by abnormal loading conditions. While this approach broadens the scope of the Guidelines and makes some recommendations more complex, it aligns with everyday clinical practice and is more likely to improve diagnostic accuracy and treatment.

2.2 Scope of Guidelines

Uniquely for a common cardiovascular disease, there are very few randomized, controlled, clinical trials in patients with HCM.2 For this reason, the majority of the recommendations in this document are based on observational cohort studies and expert consensus opinion. The aim is to provide healthcare professionals with a practical diagnostic and treatment framework for patients of all ages and, as the majority of patients have a genetic cause for their disease, the Guidelines also consider the implications of a diagnosis for families and provide specific advice on reproduction and contraception.

Adoption of a purely morphological disease definition means that the number of possible aetiologies is considerable, particularly in young children. As it is impractical to provide an exhaustive compendium of all possible causes of HCM, the Guidelines focus on the most common genetic and non-genetic subtypes, but additional references for less common disorders are provided. Similarly,
treatment recommendations focus largely on generic management issues but make reference to rare diseases when appropriate.

3. Epidemiology
A number of methodologically diverse studies in North America, Europe, Asia and Africa report a prevalence of unexplained increase in LV thickness in the range of 0.02–0.23% in adults (Web Table 1). Many show an age-related prevalence, with much lower rates in patients diagnosed under the age of 25 years. In paediatric registries, the prevalence of HCM in children is unknown, but population-based studies report an annual incidence of 0.3 to 0.5 per 100,000 (Web Table 1). While HCM is most frequently transmitted as an autosomal-dominant trait (see section 6: Genetic testing and family screening) most studies report a small male preponderance (Web Table 1). This finding remains unexplained but might reflect bias in screening strategies as well as genetic and hormonal modifiers. The prevalence of HCM in different racial groups is similar.

4. Aetiology
In up to 60% of adolescents and adults with HCM, the disease is an autosomal dominant trait caused by mutations in cardiac sarcomere protein genes. Five to ten percent of adult cases are caused by other genetic disorders including inherited metabolic and neuromuscular diseases, chromosome abnormalities and genetic syndromes (Figure 1; Web Tables 2 and 3). Some patients have non-genetic disorders that mimic genetic forms of the disease, for example, senile (TTR) and (AL) amyloidosis.

4.1 Sarcomere protein gene mutations
Mutations in the genes encoding beta-myosin heavy chain (MYH7) and myosin-binding protein C (MYBPC3) account for the majority of cases; less commonly affected genes include cardiac troponin I and T (TNNI3, TNNT2), tropomyosin alpha-1 chain (TPM1) and myosin light chain 3 (MYL3). In general, patients with a sarcomere protein mutation present earlier and report a higher prevalence of family history of HCM and sudden cardiac death (SCD) than those without a mutation. They also tend to have more severe hypertrophy, microvascular dysfunction and myocardial fibrosis. Several studies have suggested that some sarcomeric protein mutations are associated with a poorer prognosis than others, but these observations are based on small numbers of affected individuals, are sometimes inconsistent between studies, and are limited by the rarity of individual mutations.

4.2 Metabolic disorders
Many inherited metabolic diseases are associated with LV hypertrophy. Most are inherited as autosomal recessive traits, but a few are X-linked (Figure 1; Web Table 3). The most common metabolic disorders in adults with HCM are Anderson-Fabry disease, with a prevalence of around 0.5–1% in patients older than 35–40 years, and disease caused by mutations in the gene encoding the γ2 sub-unit of the adenosine monophosphate-activated protein kinase (PRKAG2), with a prevalence of approximately 1%. The reported prevalence of lysosome-associated membrane protein 2 (LAMP-2) mutations that cause Danon disease ranges from 0.7–2.7%. Although still rare, metabolic disorders account for a greater proportion of HCM in children and adolescents.

4.3 Mitochondrial cardiomyopathies
Primary mitochondrial disorders are caused by mutations in nuclear or mitochondrial DNA that are transmitted as autosomal dominant, autosomal recessive, X-linked and maternally inherited traits. The most frequent are those caused by mutations in genes that code for the respiratory chain protein complexes (Web Table 3). The clinical presentation of mitochondrial disease typically varies in age at onset and in the range and severity of organ involvement.

4.4 Neuromuscular disease
With the exception of Friedreich’s ataxia, HCM is a rare manifestation of neuromuscular disease (Figure 1; Web Table 3). It is reported in some muscular dystrophies and congenital skeletal myopathies (e.g. nemaline myopathy) (Web Table 3) and in association with muscle weakness and contractures caused by mutations in the four-and-half LIM domain-1 (FHL-1) gene. Desmin gene mutations typically cause dilated and restrictive cardiomyopathies, but can present with HCM and atrioventricular (AV) block.

4.5 Malformation syndromes
Several malformation syndromes are associated with HCM (Web Table 3). The most common are those caused by mutations in genes that code for proteins of the Ras/mitogen activated protein kinase (MAPK) pathway including Noonan, LEOPARD (Lentigines, ECG abnormalities, Ocular hypertelorism, Pulmonary stenosis, Abnormal genitalia, Retardation of growth, and sensorineural Deafness) and Costello syndromes. Most are diagnosed in childhood, but some milder forms (particularly Noonan syndrome) escape early detection and are identified later in life.

4.6 Infiltrative disease/inflammation
Cardiac amyloidosis results in a progressive increase in the thickness of the left and right ventricular myocardium, interatrial septum and AV valves. Light chain (AL) and hereditary transthyretin (TTR)-related amyloidoses can affect the heart in isolation or with multi-organ involvement, whereas wild type (senile) TTR amyloidosis predominantly affects the heart and the carpal tunnel ligament. Myocardial oedema and cellular infiltration in acute myocarditis can mimic HCM, but this is usually a transient phenomenon, accompanied by other clinical and laboratory findings suggestive of the diagnosis.

4.7 Endocrine disorders
Transient ventricular hypertrophy is seen in infants of mothers with diabetes, even after good diabetic control during pregnancy. In adults, left ventricular hypertrophy (LVH) is reported in association with phaeochromocytoma and acromegaly, but treatment of the underlying endocrine disorder usually results in resolution of hypertrophy.
4.8 Drugs

Chronic use of some drugs, including anabolic steroids, tacrolimus and hydroxychloroquine, can cause LVH although they rarely result in a left ventricular wall thickness \( \geq 1.5 \text{ cm} \).55–57

5. Diagnosis

The diagnosis of HCM rests on the detection of increased LV wall thickness by any imaging modality, but the disease phenotype also includes myocardial fibrosis, morphologic abnormalities of the mitral valve apparatus, abnormal coronary microcirculatory function and electrocardiographic abnormalities. Due to the diverse etiology of the disease, detection of increased LV wall thickness that is unexplained by loading conditions should prompt a systematic search for its underlying cause. In many patients, this work-up should include specialized laboratory testing and, in some circumstances, genetic analysis (Figure 2).

5.1 Diagnostic criteria

5.1.1 Adults

In an adult, HCM is defined by a wall thickness \( \geq 15 \text{ mm} \) in one or more LV myocardial segments—as measured by any imaging technique (echocardiography, cardiac magnetic resonance imaging (CMR) or computed tomography (CT))—that is not explained solely by loading conditions.

Genetic and non-genetic disorders can present with lesser degrees of wall thickening (13–14 mm); in these cases, the diagnosis of HCM requires evaluation of other features including family history, non-cardiac symptoms and signs, electrocardiogram (ECG) abnormalities, laboratory tests and multi-modality cardiac imaging.

Common diagnostic challenges include the following:

- Presentation in the late phase of the disease with a dilated and/or hypokinetic left ventricle and LV wall thinning (see section 8.2).
- Physiological hypertrophy caused by intense athletic training (see section 12.1).
- Patients with co-existent pathologies (see section 12.2 on hypertension and section 12.4 on diagnosis and management of valve disease).
- Isolated basal septal hypertrophy in elderly people (see section 12.3).

5.1.2 Children

As in adults, the diagnosis of HCM requires an LV wall thickness more than two standard deviations greater than the predicted mean (z-score \( \geq 2 \), where a z-score is defined as the number of standard deviations from the population mean).58
5.1.3 Relatives

The clinical diagnosis of HCM in first-degree relatives of patients with unequivocal disease (LVH ≥ 15 mm) is based on the presence of otherwise unexplained increased LV wall thickness ≥ 13 mm in one or more LV myocardial segments, as measured using any cardiac imaging technique (echocardiography, cardiac magnetic resonance (CMR) or CT).

In families with genetic forms of HCM, mutation carriers can have non-diagnostic morphological abnormalities that are sometimes associated with abnormal ECG findings. While the specificity of such abnormalities is low, in the context of familial disease they can represent early or mild expression of the disease, and the presence of multiple features increases the accuracy for predicting disease in genotyped populations.

5.2 History and physical examination

Age is one of the most important factors to take into account when considering the possible causes for HCM. For example, inherited metabolic disorders and congenital dysmorphic syndromes are much more common in neonates and infants than in older children or adults, whereas wild-type TTR-related amyloidosis is a disease mostly of men over the age of 65 years.

Construction of a three- to four-generation family pedigree helps to confirm a genetic origin of disease and identifies other family members that are at risk of disease development. Specific features to note in the family history include sudden cardiac deaths, unexplained heart failure, cardiac transplantation, pacemaker and defibrillator implants, and evidence for systemic disease (stroke at a young age, skeletal muscle weakness, renal dysfunction, diabetes, deafness, etc.). Pedigree analysis can also determine the likely mode of inheritance. Most genetic forms of HCM are autosomal-dominant and are therefore characterized by the presence of affected individuals in every generation, with transmission from parents of either sex (including male to male) and a 50% risk to offspring. X-linked inheritance should be suspected if males are the only or most severely affected individuals and there is no male-to-male transmission. Autosomal recessive inheritance, the least common pattern, is likely when both parents of the proband are unaffected and consanguineous. When women—but not men—transmit the disease to children of either sex, mitochondrial DNA mutations should be considered.

Many individuals with HCM complain of few, if any, symptoms. In such cases the diagnosis can be incidental or the result of screening. Some patients experience angina, dyspnoea, palpitations and
syncope (see section 8: Assessment of symptoms). A number of non-cardiac symptoms act as pointers for specific diagnoses (Table 3).

Similarly, general physical examination can provide diagnostic clues in patients with syndromic or metabolic causes of HCM. Paradoxically, cardiovascular examination is often normal but, in patients with LV outflow tract obstruction (LVOTO), a number of typical features may be identified including a rapid up-and-down stroke to the arterial pulse and an ejection systolic murmur at the left sternal edge that radiates to the right upper sternal edge and apex. The intensity of the murmur is increased by manoeuvres that reduce ventricular preload or afterload, such as standing up from the squatting position or the murmur is increased by manoeuvres that reduce ventricular preload or afterload, such as standing up from the squatting position and sensorineural deafness; TTR

<table>
<thead>
<tr>
<th>Symptom/sign</th>
<th>Diagnosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Learning difficulties, mental retardation</td>
<td>Mitochondrial diseases, Noonan/LEOPARD/Costello syndrome, Danon disease</td>
</tr>
<tr>
<td>Sensorineural deafness</td>
<td>Mitochondrial diseases (particularly with diabetes), Anderson-Fabry disease, LEOPARD syndrome</td>
</tr>
<tr>
<td>Visual impairment</td>
<td>Mitochondrial diseases (retinal disease, optic nerve atrophy), TTR-related amyloidosis (cotton wool type vitreous opacities), Danon disease (retinitis pigmentosa), Anderson-Fabry disease (cataracts, corneal opacities)</td>
</tr>
<tr>
<td>Gait disturbance</td>
<td>Friedreich's ataxia</td>
</tr>
<tr>
<td>Paraesthesia/sensory abnormalities/neuropathic pain</td>
<td>Amyloidosis, Anderson-Fabry disease</td>
</tr>
<tr>
<td>Carpal tunnel syndrome</td>
<td>TTR-related amyloidosis (especially when bilateral and in male patients)</td>
</tr>
<tr>
<td>Muscle weakness</td>
<td>Mitochondrial diseases, Glycogen storage disorders, FHL1 mutations, Friedreich’s ataxia, Pompe disease</td>
</tr>
<tr>
<td>Palpebral ptosis</td>
<td>Mitochondrial diseases, Noonan/LEOPARD syndrome, Myotonic dystrophy</td>
</tr>
<tr>
<td>Lentigines/café au lait spots</td>
<td>LEOPARD/Noonan syndrome, Noonan syndrome</td>
</tr>
<tr>
<td>Angiokeratoma, hypohidrosis</td>
<td>Anderson-Fabry disease</td>
</tr>
</tbody>
</table>

FHL1 = four and a half LIM domains 1; LEOPARD = lentigines, ECG abnormalities, ocular hypertelorism, pulmonary stenosis, abnormal genitalia, retardation of growth and sensorineural deafness; TTR = transthyretin

Table 4  Electrocardiographic abnormalities suggesting specific diagnoses or morphological variants

<table>
<thead>
<tr>
<th>Finding</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Short PR interval/pre-excitation</td>
<td>Pre-excitation is a common feature of storage diseases (Pompe, PRKAG2, and Danon) and mitochondrial disorders (MELAS, MERFF). A short PR interval without pre-excitation is seen in Anderson-Fabry disease.</td>
</tr>
<tr>
<td>AV block</td>
<td>Progressive atrioventricular conduction delay is common in mitochondrial disorders, some storage diseases (including Anderson-Fabry disease), amyloidosis, desminopathies and in patients with PRKAG2 mutations.</td>
</tr>
<tr>
<td>Extreme LVH (Sokolow score ≥50)</td>
<td>Extremely large QRS voltage is typical of storage diseases such as Pompe and Danon disease, but can be caused by pre-excitation alone.</td>
</tr>
<tr>
<td>Low QRS voltage (or normal voltages despite increased LV wall thickness)</td>
<td>Low QRS voltage in the absence of pericardial effusion, obesity and lung disease is rare in HCM (limited to cases with end-stage evolution) but is found in up to 50% of patients with AL amyloidosis and 20% with TTR amyloidosis. Differential diagnosis between HCM and cardiac amyloidosis is aided by measuring the ratio between QRS voltages and LV wall thickness.</td>
</tr>
<tr>
<td>Extreme superior (“North West”) QRS axis deviation</td>
<td>Seen in patients with Noonan syndrome who have severe basal hypertrophy extending into the RV outflow tract.</td>
</tr>
<tr>
<td>Giant negative T wave inversion (&gt;10 mm)</td>
<td>Giant negative T wave inversion in the precordial and/or inferolateral leads suggests involvement of the LV apex.</td>
</tr>
<tr>
<td>Abnormal Q waves</td>
<td>Abnormally deep Q waves in the inferolateral leads, usually with a positive T wave, are associated with an asymmetrical distribution of LVH. Q waves of abnormal duration (≥40 ms) are associated with areas of replacement fibrosis.</td>
</tr>
<tr>
<td>Coved ST segment elevation in lateral chest leads</td>
<td>Some patients with apical or distal hypertrophy develop small apical aneurysms, sometimes associated with myocardial scarring. These may only be detectable on CMR, ventriculography or contrast echo, and are occasionally associated with ST elevation in the lateral chest leads.</td>
</tr>
</tbody>
</table>

AV = atrioventricular; AL = amyloid light chain; CMR = cardiac magnetic resonance; HCM = hypertrophic cardiomyopathy; LV = left ventricular; LVH = left ventricular hypertrophy; MELAS = mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes; MERFF = myoclonic epilepsy with ragged red fibres; PRKAG2 = gamma-2 subunit of the adenosine monophosphate-activated protein kinase; RV = right ventricular; TTR = transthyretin.
5.3 Resting and ambulatory electrocardiography

The standard 12-lead ECG can be normal at presentation (6% of patients in referral cohort studies) but generally shows a variable combination of LVH, ST- and T-wave abnormalities, and pathological Q-waves. When interpreted in conjunction with findings on echocardiography and CMR imaging, features that would normally indicate other conditions, such as myocardial ischaemia or infarction, can—with age at diagnosis, inheritance pattern and associated clinical features—suggest an underlying diagnosis or provide clues to the distribution of hypertrophy and myocardial scar (Table 4). For this reason, the ECG is recommended at the first clinic visit in all individuals with known or suspected HCM and should be repeated whenever there is a change in symptoms in patients with an established diagnosis. The ECG is also a sensitive—though non-specific—early marker of disease in relatives.

The frequency of arrhythmias detected during ambulatory electrocardiographic monitoring is age-related. Asymptomatic non-sustained ventricular tachycardia (NSVT), at a rate between 120 and 200 beats per minute (BPM), occurs in 25% of adults with sustained ventricular tachycardia (NSVT), at a rate between 120 and 200 beats per minute (BPM), occurs in 25% of adults with hypertrophic cardiomyopathy (HCM). Paroxysmal supraventricular arrhythmias (PSVT) occur in 25% of adults with hypertrophic cardiomyopathy (HCM). Ambulatory ECG monitoring is recommended at the initial clinical assessment to assess the risk of sudden cardiac death (section 9.5: Sudden cardiac death) and stroke (section 9.4: Atrial tachyarrhythmia).

### Recommendations on electrocardiography

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Class</th>
<th>Level</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Standard 12-lead electrocardiography is recommended in patients with suspected hypertrophic cardiomyopathy to aid diagnosis and provide clues to underlying aetiology.</td>
<td>I</td>
<td>B</td>
<td>61,67,68</td>
</tr>
<tr>
<td>48-hour ambulatory ECG monitoring is recommended in patients at their initial clinical assessment, to detect atrial and ventricular arrhythmia.</td>
<td>I</td>
<td>B</td>
<td>69–73</td>
</tr>
</tbody>
</table>

ECG = electrocardiogram.

Class of recommendation.

Level of evidence.

Reference(s) supporting recommendations.

5.4 Echocardiography

Echocardiography is central to the diagnosis and monitoring of HCM. In most patients, hypertrophy preferentially involves the interventricular septum in the basal LV segments but often extends into the lateral wall, the posterior septum and LV apex. As increased ventricular wall thickness can be found at any location (including the right ventricle), the presence, distribution and severity of hypertrophy should be documented using a standardized protocol for cross-sectional imaging from several projections. Correct orientation and beam alignment along orthogonal planes are essential to avoid oblique sections and over-estimation of wall thickness. Measurements of LV wall thickness should be performed at end-diastole, preferably in short-axis views. M-mode measurements in the parasternal long axis projection should be avoided if possible, to prevent over-estimation of septal thickness by oblique cuts. A standardized approach to myocardial segmentation and nomenclature should be followed for all imaging modalities.

5.4.1 Assessment of left ventricular wall thickness

There are a number of echocardiographic indices that provide a semi-quantitative score of LVH, but for diagnostic purposes the single most relevant parameter is the maximum LV wall thickness at any level.

In patients with known or suspected HCM it is essential that all LV segments from base to apex be examined, ensuring that the wall thickness is recorded at mitral, mid-LV and apical levels.

Accurate assessment of LV wall thickness can be challenging when hypertrophy is confined to one or two segments, particularly in the anterolateral wall or the LV apex. In such cases, extra care is needed during imaging (e.g. transducer angulation to avoid problems related to lateral resolution and foreshortening). Similarly, meticulous imaging of the apex by parasternal and multiple apical views is required to detect apical HCM. If a segment is not visualized adequately, LV opacification—using ultrasound contrast agents and/or CMR—should be considered.

5.4.2 Associated abnormalities of the mitral valve and left ventricular outflow tract

Approximately one-third of patients have resting SAM of the mitral valve leaflets that results in obstruction to the LV outflow tract, while another third have latent obstruction only during manoeuvres that change loading conditions and LV contractility (see 5.4.3: Assessment of latent obstruction). Other morphological features that contribute to LVOTO include papillary muscle abnormalities (hypertrophy, anterior and internal displacement, direct insertion into the anterior mitral valve leaflet) and mitral leaflet abnormalities such as elongation or accessory tissue. Although dynamic LVOTO is common in patients with HCM, it also occurs in other circumstances, such as calcification of the posterior mitral annulus, hypertension, hypovolaemia and hypercontractile states.

By convention, LVOTO is defined as an instantaneous peak Doppler LV outflow tract pressure gradient ≥30 mm Hg at rest or during physiological provocation such as Valsalva manoeuvre, standing and exercise. A gradient of ≥50 mm Hg is usually considered to be the threshold at which LVOTO becomes haemodynamically important. This concept comes from studies that demonstrate progressive impedance to flow above this value.

When a gradient is detected in the LV cavity, it is important to systematically exclude obstruction that is unrelated to SAM, including sub-aortic membranes, mitral valve leaflet abnormalities and mid-cavity obstruction, particularly when interventions to relieve LV outflow obstruction are contemplated.

Systematic two-dimensional (2D) and Doppler echocardiography is usually sufficient to determine the mechanism and severity of
LVOTO but, when non-invasive images are poor, transoesophageal echocardiography (TOE) or invasive pressure measurements combined with CMR may be considered in selected patients.

Systolic anterior motion of the mitral valve nearly always results in failure of normal leaflet coaptation and mitral regurgitation, which is typically mid-to-late systolic and inferolaterally oriented; measurement of the velocity and timing of the mitral jet helps to differentiate it from LV outflow tract turbulence. SAM-related mitral regurgitation is inherently dynamic in nature and its severity varies with the degree of LVOTO.78,91,92

The presence of a central- or anteriorly directed jet of mitral regurgitation should raise suspicion of an intrinsic mitral valve abnormality and prompt further assessment with TOE if necessary.

5.4.3 Assessment of latent obstruction
Identification of LVOTO is important in the management of symptoms and assessment of sudden cardiac death risk (see section 9.5: Sudden cardiac death). 2D and Doppler echocardiography during a Valsalva manoeuvre in the sitting and semi-supine position—and then on standing if no gradient is provoked—is recommended in all patients (Figure 3).78,93 Exercise stress echocardiography is recommended in symptomatic patients if bedside manoeuvres fail to induce LVOTO ≥50 mm Hg. Pharmacological provocation with dobutamine is not recommended, as it is not physiological and can be poorly tolerated. Similarly, nitrates do not reproduce exercise-induced gradients and should be reserved for patients who cannot perform physiologically stressful procedures.94 There is some evidence that post-prandial gradients are higher than those performed in the fasting state and pre-treatment with β-blockers often reduces the incidence and severity of exercise-induced LV outflow tract gradients.95 Since there are relatively few data comparing stress echocardiography protocols,93,95–98 laboratories should develop and validate their own and ensure that staff are properly trained in the procedure.

In asymptomatic patients, bedside provocation manoeuvres are useful in risk stratification (see section 9.5: Sudden cardiac death) but routine exercise stress echocardiography in this situation has not been prospectively evaluated and should only be considered in selected patients when the presence of a LVOT gradient is relevant to lifestyle advice and decisions on medical treatment.

5.4.4 Left atrial enlargement
The left atrium (LA) is often enlarged, and its size provides important prognostic information.72,73,99 Although most published studies use anteroposterior LA diameter,100 comparable findings using LA volume indexed to body surface area are reported.101,102

Figure 3 Protocol for the assessment and treatment of left ventricular outflow tract obstruction.
cause of LA enlargement is multifactorial, but the most common mechanisms are SAM-related mitral regurgitation and elevated LV filling pressures.

5.4.5 Assessment of diastolic function
Patients with HCM often have diastolic dysfunction and the assessment of LV filling pressures is helpful in the evaluation of symptoms and disease staging. Doppler echocardiographic parameters are sensitive measures of diastolic function, but are influenced by loading conditions, heart rate and age, and there is no single echocardiographic parameter that can be used as a diagnostic hallmark of LV diastolic dysfunction.103 Therefore, a comprehensive evaluation of diastolic function—including Doppler myocardial imaging, pulmonary vein flow velocities, pulmonary artery systolic pressure and LA size—is recommended as part of the routine assessment of HCM.103 Patients with a restrictive LV filling pattern (ratio of mitral peak velocity of early filling (E) to mitral peak velocity of late filling (A) ≥ 2; E-wave deceleration time ≤ 150 ms) may be at higher risk for adverse outcome, even with a preserved ejection fraction (EF).104,105 Data on the relationship between non-invasive Doppler myocardial imaging-derived estimates of LV filling pressure and invasive pressure studies are contradictory,106 but some studies show correlation between an elevated ratio of early transmural flow velocity (E) to early mitral annulus velocity (e′) >12–15 and raised LV end-diastolic pressure, exercise capacity and prognosis.107,108

5.4.6 Systolic function
Radial contractile function (EF or fractional shortening) is typically normal or increased in patients with HCM. However, EF is a poor measure of LV systolic performance when hypertrophy is present.109 Myocardial longitudinal velocities and deformation parameters (strain and strain rate), derived from Doppler myocardial imaging or speckle tracking techniques, are often reduced despite a normal EF and may be abnormal before the development of increased wall thickness in genetically affected relatives. Myocardial longitudinal deformation is typically reduced at the site of hypertrophy.110

5.4.7 Value of echocardiography in differential diagnosis
A number of echocardiographic features can point to a specific diagnosis (Table 5).67 Concentric hypertrophy is more common in metabolic and infiltrative disorders and biventricular hypertrophy and obstruction to the outflow of both ventricles is frequent in Noonan syndrome and associated disorders. Clues that suggest myocardial storage disease or infiltration include sparking or granular myocardial texture, small pericardial effusion, thickening of the interatrial septum, nodular thickening of the aortic valve, and mildly reduced EF with restrictive physiology.

5.4.8 Contrast echocardiography
Apical hypertrophy may be overlooked due to near-field artefacts. Poor visualization of the lateral LV wall may also obscure localized hypertrophy. In cases of doubt, intravenous ultrasound contrast agents should be used to outline the endocardium.81

In all patients undergoing septal alcohol ablation (SAA), intracoronary contrast echocardiography is recommended to ensure correct localization of alcohol (see section 9.1.3.2: Septal alcohol ablation).111–113

5.4.9 Transoesophageal echocardiography
Transoesophageal echocardiography should be considered in patients with poor transthoracic echo windows, as an alternative or complementary investigation to CMR. It is particularly useful in patients with LVOTO if the mechanism is unclear, when assessing the mitral valve apparatus before a septal reduction procedure, and when severe mitral regurgitation caused by intrinsic valve abnormalities is suspected.114–117 In patients undergoing septal myectomy, peroperative TOE should be used to guide the surgical strategy and to detect surgical complications (ventricular septal defect and aortic regurgitation (AR)) and residual LVOTO.116–118 Rarely, TOE with intracoronary contrast injection of the candidate septal perforator arteries is necessary to guide septal alcohol ablation when transthoracic windows are insufficient to visualize contrast within the myocardium.
Recommendations for transthoracic echocardiographic evaluation in hypertrophic cardiomyopathy

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Class</th>
<th>Level</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>In all patients with HCM at initial evaluation, transthoracic 2D and Doppler echocardiography are recommended, at rest and during Valsalva manoeuvre in the sitting and semi-supine positions—and then on standing if no gradient is provoked.</td>
<td>I</td>
<td>B</td>
<td>72–74,76, 78,82,83, 99,119–121</td>
</tr>
<tr>
<td>Measurement of maximum diastolic wall thickness is recommended, using 2D short-axis views in all LV segments, from base to apex.</td>
<td>I</td>
<td>C</td>
<td>74–80</td>
</tr>
<tr>
<td>A comprehensive evaluation of LV diastolic function is recommended, including pulsed Doppler of mitral valve inflow, tissue Doppler velocities at the mitral annulus, pulmonary vein flow velocities, pulmonary artery systolic pressure, and measurement of LA size and volume.</td>
<td>I</td>
<td>C</td>
<td>103–105</td>
</tr>
<tr>
<td>In symptomatic patients with a resting or provoked peak instantaneous LV outflow tract gradient &lt;50 mm Hg, 2D and Doppler echocardiography during exercise in the standing, sitting or semi-supine position is recommended to detect provokable LVOTO and exercise-induced mitral regurgitation.</td>
<td>I</td>
<td>B</td>
<td>84,85,93,94</td>
</tr>
<tr>
<td>In asymptomatic patients with a resting or provoked peak instantaneous LV outflow tract gradient &lt;50 mm Hg, 2D and Doppler echocardiography during exercise—in the standing, sitting or semi-supine positions—may be considered when the presence of an LVOT gradient is relevant to lifestyle advice and decisions on medical treatment.</td>
<td>IIb</td>
<td>C</td>
<td>84,85,93,94</td>
</tr>
<tr>
<td>In patients with sub-optimal images or with suspected LV apical hypertrophy or aneurysm, TTE with LV cavity opacification—using intravenous echocardiographic contrast agents—should be considered as an alternative to CMR imaging.</td>
<td>IIa</td>
<td>C</td>
<td>81</td>
</tr>
</tbody>
</table>

LVOTO = left ventricular outflow tract obstruction; LA = left atrium; LV = left ventricle; LVOTO = left ventricular outflow tract obstruction; SAA = septal alcohol ablation; TTE = transthoracic echocardiography.

Recommendations on transoesophageal echocardiography

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Class</th>
<th>Level</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Perioperative TOE is recommended in patients undergoing septal myectomy, to confirm the mechanism of LVOTO, to guide the surgical strategy, to assess post-surgical complications and to detect residual LV outflow tract obstruction.</td>
<td>I</td>
<td>C</td>
<td>114–118</td>
</tr>
<tr>
<td>TOE should be considered in patients with LVOTO if the mechanism is unclear, or when assessing the mitral valve apparatus before a septal reduction procedure, or when severe mitral regurgitation, caused by intrinsic valve abnormalities, is suspected.</td>
<td>IIa</td>
<td>C</td>
<td>114–117</td>
</tr>
<tr>
<td>TOE with intracoronary contrast injection of the candidate septal perforator artery should be considered to guide septal alcohol ablation when transthoracic windows are insufficient for proper visualization of echo-contrast within the myocardium.</td>
<td>IIa</td>
<td>C</td>
<td>122</td>
</tr>
</tbody>
</table>

LVOTO = left ventricular outflow tract obstruction; TOE = transoesophageal echocardiography.

5.5 Cardiovascular magnetic resonance imaging

Cardiovascular magnetic resonance imaging embraces several modalities that provide detailed information on cardiac morphology, ventricular function and myocardial tissue characteristics. Cardiovascular magnetic resonance evaluation of patients with known or suspected HCM should be in line with current ESC recommendations (http://www.escardio.org/communities/EACVI) and should be performed and interpreted by teams experienced in cardiac imaging and in the evaluation of heart muscle disease.

5.5.1 Assessment of ventricular morphology and function

CMR should be considered in patients with HCM at their baseline assessment if local resources and expertise permit.
In patients with good echocardiographic images, CMR provides similar information on ventricular function and morphology, but it is helpful in establishing the diagnosis of HCM in patients with poor acoustic windows or when some LV regions are poorly visualized—such as the anterolateral wall, the LV apex and the right ventricle. As in 2D echocardiography, over-estimation of wall thickness can result from oblique sections (particularly at the LV apex) or from inclusion of paraskeletal structures such as the moderator band or false tendons. Over-estimation of wall thickness is also possible in spoiled gradient echo images and so steady-state free precession (SSFP) cine sequences are preferred. Cardiovascular magnetic resonance imaging is superior to transthoracic echocardiography (TTE) in the measurement of LV mass, but LV mass itself correlates weakly with maximal wall thickness and can be normal in patients with asymmetric HCM, especially when it involves less than two LV segments. Cardiovascular magnetic resonance imaging is superior to standard 2D echocardiography in the detection of LV apical and anterolateral hypertrophy, aneurysms and thrombi, and is more sensitive in the detection of subtle markers of disease, such as myocardial crypts and papillary muscle abnormalities in patients with sarcomeric protein gene mutations.

Phase velocity flow mapping sequences can be used to determine the peak velocity of blood flow through the LV outflow tract in patients with LVOTO, but proper alignment of the imaging plane, to obtain the highest flow velocities is time-consuming and prone to error. Intravoxel dephasing and signal loss due to phase offset errors, also make the accurate quantification of turbulent flow difficult and LV outflow gradients can only be measured at rest. For these reasons, Doppler echocardiography is the modality of choice for quantification of LVOTO. Similarly, while mitral inflow velocities and pulmonary vein flow derived from phase contrast CMR (PC-CMR) provide highly reproducible and accurate data in experienced hands, echocardiography is the preferred method for assessment of diastolic function in routine practice.

In selected cases where echocardiographic images are suboptimal, CMR is helpful in pre-operative planning for surgical myectomy, particularly in patients with multi-level LV obstruction (LV outflow tract and mid-cavity) and in patients with right ventricular (RV) outflow tract abnormalities. CMR can also quantify the amount of tissue necrosis induced by septal alcohol ablation, as well as the outflow tract abnormalities. CMR can also quantify the amount of tissue necrosis induced by septal alcohol ablation, as well as the outflow tract abnormalities. CMR with LGE may be considered in patients fulfilling diagnostic criteria for HCM, to assess cardiac anatomy, ventricular function, and the presence and distribution of hypertrophy and at the anterior and posterior RV insertion points. Late gadolinium enhancement is unusual in non-hypertrophied segments except in advanced stages of disease, when full-thickness LGE in association with wall thinning is common. Late gadolinium enhancement may be associated with increased myocardial stiffness and adverse LV remodelling and the extent of LGE is associated with a higher incidence of regional wall motion abnormalities. Late gadolinium enhancement varies substantially with the quantification method used and the 2-standard deviation technique is the only one validated against necropsy.

### 5.5.3 Late Gadolinium Enhancement and Prognosis

The association between LGE and long-term outcomes has been examined in six studies, four of which are included in a meta-analysis (Web Table 4). All published studies are limited by selection and referral bias, incomplete risk assessment and differences in scanning protocols and LGE quantification. The pooled data support a relationship between LGE and cardiovascular mortality, heart failure death and all-cause death, but show only a trend towards an increased risk of SCD. Late gadolinium enhancement is associated with NSVT on Holter monitoring.

On balance, the extent of LGE on CMR has some utility in predicting cardiovascular mortality, but current data do not support the use of LGE in prediction of SCD risk.

### 5.5.4 Differential diagnosis

Cardiac magnetic resonance imaging rarely distinguishes the causes of HCM by their magnetic properties alone, but the distribution and severity of interstitial expansion can, in context, suggest specific diagnoses. Anderson-Fabry disease is characterized by a reduction in non-contrast T1 signal and the presence of posterolateral LGE. In cardiac amyloidosis, there is often global, sub-endocardial or segmental LGE and a highly specific pattern of myocardial and blood-pool gadolinium kinetics caused by similar myocardial and blood T1 signals.

The absence of fibrosis may be helpful in differentiating HCM from physiological adaptation in athletes, but LGE may be absent in people with HCM, particularly the young and those with mild disease.

### Recommendations for cardiovascular magnetic resonance evaluation in hypertrophic cardiomyopathy

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Class</th>
<th>Level</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>It is recommended that CMR studies be performed and interpreted by teams experienced in cardiac imaging and in the evaluation of heart muscle disease.</td>
<td>I</td>
<td>C</td>
<td>148,149</td>
</tr>
<tr>
<td>In the absence of contraindications, CMR with LGE is recommended in patients with suspected HCM who have inadequate echocardiographic windows, in order to confirm the diagnosis.</td>
<td>I</td>
<td>B</td>
<td>126,127</td>
</tr>
<tr>
<td>In the absence of contraindications, CMR with LGE should be considered in patients fulfilling diagnostic criteria for HCM, to assess cardiac anatomy, ventricular function, and the presence and extent of myocardial fibrosis.</td>
<td>IIa</td>
<td>B</td>
<td>124,126,127,130,136,138–143</td>
</tr>
<tr>
<td>CMR with LGE imaging should be considered in patients with suspected apical hypertrophy or aneurysm.</td>
<td>IIa</td>
<td>C</td>
<td>127,129</td>
</tr>
<tr>
<td>CMR with LGE imaging should be considered in patients with suspected cardiac amyloidosis.</td>
<td>IIa</td>
<td>C</td>
<td>22,147</td>
</tr>
<tr>
<td>CMR with LGE may be considered before septal alcohol ablation or myectomy, to assess the extent and distribution of hypertrophy and myocardial fibrosis.</td>
<td>IIb</td>
<td>C</td>
<td>150,151</td>
</tr>
</tbody>
</table>

CMR = cardiac magnetic resonance; HCM = hypertrophic cardiomyopathy; LGE = late gadolinium enhancement.

Class of recommendation.

Level of evidence.

Reference(s) supporting recommendations.
5.6 Nuclear imaging and computerized tomography

Nuclear imaging, including positron emission tomography (PET), has been used to measure myocardial blood flow and to detect myocardial perfusion defects in patients with HCM, but its value in the diagnosis of HCM is limited. The major clinical contribution of nuclear imaging is the detection of TTR-related cardiac amyloidosis. Transthyretin is a tetrameric plasma transport protein synthesized in the liver and is the precursor protein in senile systemic amyloidosis and familial TTR-related amyloidosis. Several studies have suggested that TTR-derived fibrils show avidity for bone tracers, in particular 99mTc-Technetium-3,3-diphosphono-1,2-propano-di-carboxylic acid (99mTc-DPD), whereas there is no uptake of tracer in the hearts of patients with HCM caused by sarcomeric protein gene mutations. For this reason, bone scintigraphy (ideally with 99mTc-DPD) should be considered in patients in whom TTR amyloidosis is a possibility (age >65 years, history of bilateral carpal tunnel syndrome, absent family history of HCM, and features consistent with cardiac amyloidosis on ECG and cardiac imaging).

The high contrast resolution of CT provides clear delineation of the myocardium and accurate measurement of wall thickness, ventricular volumes, ejection fraction and LV mass, which correlate well with magnetic resonance imaging, echocardiography and gated SPECT. Cardiovascular CT permits the simultaneous imaging of the coronary arteries and valves and can be used to guide catheter ablation of supraventricular arrhythmia. Data on myocardial tissue characterization in small cohorts suggest that contrast CT may be useful in the detection of replacement myocardial fibrosis but this requires further study. Cardiac CT should be considered in patients for whom there are inadequate echocardiographic imaging and contraindications for CMR.

Recommendations for nuclear scintigraphy

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Classa</th>
<th>Levelb</th>
<th>Ref.c</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bone scintigraphy (particularly with 99mTc-DPD) should be considered in patients with symptoms, signs and non-invasive tests consistent with TTR-related amyloidosis.</td>
<td>IIa</td>
<td>B</td>
<td>156–158</td>
</tr>
<tr>
<td>Cardiac CT should be considered in patients who have inadequate echocardiographic imaging and contraindications for CMR.</td>
<td>IIa</td>
<td>C</td>
<td>159</td>
</tr>
</tbody>
</table>

CT = computerized tomography; 99mTc-DPD = 99mTc-Technetium-3,3-diphosphono-1,2-propano-di-carboxylic acid; TTR = transthyretin.

5.7 Endomyocardial biopsy

Many of the genetic and non-genetic causes of HCM have characteristic histological appearances, but the diagnosis of HCM is clinical and relies on non-invasive testing in the first instance. As the underlying aetiology can usually be determined using clinical assessment, pedigree analysis, non-invasive imaging, laboratory testing and molecular genetic analysis, endomyocardial biopsy is not part of the routine diagnostic work-up, but it may be considered in clinical scenarios where myocardial infiltration or storage is suspected following specialized tests (including biopsy of other more accessible tissues).

Recommendations for endomyocardial biopsy

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Classa</th>
<th>Levelb</th>
<th>Ref.c</th>
</tr>
</thead>
<tbody>
<tr>
<td>Endomyocardial biopsy may be considered when the results of other clinical assessments suggest myocardial infiltration, inflammation or storage that cannot be confirmed by other means.</td>
<td>IIIb</td>
<td>C</td>
<td>162,163</td>
</tr>
</tbody>
</table>

aClass of recommendation. bLevel of evidence. cReference(s) supporting recommendations.

5.8 Laboratory tests

Routine laboratory testing aids the detection of extra-cardiac conditions that cause or exacerbate ventricular dysfunction (for example, thyroid disease, renal dysfunction and diabetes mellitus) and secondary organ dysfunction in patients with severe heart failure. High levels of brain natriuretic peptide (BNP), N-terminal pro-brain natriuretic peptide (NT-proBNP) and high sensitivity cardiac troponin T (hs-cTnT) are associated with cardiovascular events, heart failure and death. Despite comparable values of ventricular wall thickness, plasma BNP values are three to five times as high in patients with cardiac amyloidosis as those in other causes of HCM. A list of recommended laboratory tests is shown in Table 6.

First-line laboratory screening in children is similar to that for adults and should include haematology, glucose, cardiac enzymes (creatine kinase, aspartate aminotransferase, alanine aminotransferase, lactate dehydrogenase), renal and liver function tests, pH, electrolytes and uric acid. Following specialist evaluation, additional tests are often required, including measurement of lactate, pyruvate, ammonia, ketones, free fatty acids, carnitine profile, urine organic acids and amino acids.

6. Genetic testing and family screening

In the majority of cases, HCM is inherited as an autosomal dominant genetic trait with a 50% risk of transmission to offspring. Some cases are explained by de novo mutations, but apparently sporadic cases can arise because of incomplete penetrance in a parent and, less commonly, autosomal recessive inheritance. In patients fulfilling HCM diagnostic criteria, sequencing of sarcomere protein genes identifies a disease-causing mutation in up to 60% of cases. The likelihood of finding a causal mutation is highest in patients with familial disease and lowest in older patients and individuals with non-classical features.
6.1 Counselling in probands

Genetic counselling is recommended in all patients when HCM cannot be explained solely by a non-genetic cause.168

Counselling should be performed by trained healthcare professionals, working within multidisciplinary teams, to help patients understand and manage the psychological, social, professional, ethical and legal implications of a genetic disease.169 – 173 Counselling also facilitates the gathering of information from other family members, including cardiac and non-cardiac symptoms and autopsy reports that can be used to construct a detailed family pedigree. Pedigree analysis helps to determine the probability of familial disease and the likely mode of inheritance, and provides clues to the underlying aetiology.174 The consequences of a positive test for the patient and their relatives should be explained, and patients should be provided with information on patient support groups and other sources of information including approved websites.

### Table 6  Recommended laboratory tests in adult patients with hypertrophic cardiomyopathy

<table>
<thead>
<tr>
<th>Test</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Haemoglobin</td>
<td>• Anaemia exacerbates chest pain and dyspnoea and should be excluded whenever there is a change in symptoms.</td>
</tr>
<tr>
<td>Renal function</td>
<td>• Renal function may be impaired in patients with severe left ventricular impairment.</td>
</tr>
<tr>
<td></td>
<td>• Impaired GFR and proteinuria may be seen in amyloidosis, Anderson-Fabry disease and mitochondrial DNA disorders.</td>
</tr>
<tr>
<td>Liver transaminases</td>
<td>• Liver tests may be abnormal in mitochondrial disorders, Danon disease and β-oxidation defects.</td>
</tr>
<tr>
<td>Creatine phosphokinase</td>
<td>• Serum creatine phosphokinase is raised in metabolic disorders such as Danon and mitochondrial disease.</td>
</tr>
<tr>
<td>Plasma/leucocyte alpha galactosidase A (in men aged &gt;30 years)</td>
<td>• Low (&lt;10% normal values) or undetectable plasma and leucocyte alpha galactosidase A is present in male patients with Anderson-Fabry disease.1</td>
</tr>
<tr>
<td></td>
<td>• Plasma and leucocyte enzyme levels are often within the normal range in affected females and so genetic testing may be considered if clinically suspected.</td>
</tr>
<tr>
<td>Serum immunoglobulin free light chain assay, serum and urine immunofixation, and urine electrophoresis</td>
<td>• Should be considered if amyloidosis is suspected from history and non-invasive tests. Confirmation of the diagnosis usually requires histological analysis.</td>
</tr>
<tr>
<td>Fasting glucose</td>
<td>• May be elevated in some mitochondrial DNA disorders</td>
</tr>
<tr>
<td></td>
<td>• May be low in fatty acid and carnitine disorders.</td>
</tr>
<tr>
<td>Brain natriuretic peptide and troponin T</td>
<td>• Elevated plasma levels of BNP, NT-proBNP and troponin T are associated with higher risk of cardiovascular events, heart failure and death.</td>
</tr>
<tr>
<td>Thyroid function tests</td>
<td>• Should be measured at diagnosis and monitored every 6 months in patients treated with amiodarone.</td>
</tr>
<tr>
<td>Plasma Lactate</td>
<td>• Elevated in some patients with mitochondrial disorders.</td>
</tr>
</tbody>
</table>

### Recommendations on genetic counselling

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Class</th>
<th>Level</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Genetic counselling is recommended for all patients with HCM when their disease cannot be explained solely by a non-genetic cause, whether or not clinical or genetic testing will be used to screen family members.</td>
<td>I</td>
<td>B</td>
<td>169–173</td>
</tr>
<tr>
<td>Genetic counselling should be performed by professionals trained for this specific task working within a multidisciplinary specialist team.</td>
<td>IIa</td>
<td>C</td>
<td>168–173</td>
</tr>
</tbody>
</table>

HCM = hypertrophic cardiomyopathy.

*Class of recommendation.

*Level of evidence.

*Reference(s) supporting recommendations.

### 6.2 Methods for molecular genetic screening in probands

Conventional genetic practice uses pedigree analysis and clinical evaluation to target molecular testing to the most likely diagnosis. New, high-throughput sequencing (HTS) technologies, capable of analysing entire exomes at similar cost and accuracy to conventional sequencing methods, offer an alternative approach in which no *a priori* assumptions are made about the cause of disease.174,175 However, screening large numbers of genes results in the identification of many rare non-synonymous genetic variants of unknown significance.172 – 175 An intermediate approach is the analysis of a predefined panel of HCM-related genes using HTS, but the benefit compared with other strategies remains to be determined.19 Irrespective of the sequencing methodology employed, genetic analysis should include the most commonly implicated sarcomere protein genes (Figure 1; Web Table 2). In patients who have features suggestive of specific rare genetic diseases (see section 5) there should be a rational search for pathogenic mutations in other genes. All mutation analyses should comply with the general principles of genetic testing and diagnostic tests should be conducted by certified laboratories using validated methods of genetic analysis and reporting.169 – 173

### 6.3 Indications for genetic testing in probands

The task force acknowledge that limited resources make implementation of genetic testing challenging in some healthcare systems. Nevertheless, identification of causative mutations facilitates presymptomatic diagnosis of family members, clinical surveillance and reproductive advice.
For this reason, genetic testing is recommended in patients fulfilling diagnostic criteria for HCM to enable cascade genetic screening of their relatives.

The lack of robust data on specific genotype–phenotype associations means that the impact of genetic testing on clinical management is limited mostly to some of the rare genetic causes of HCM. Genetic testing may be of limited clinical value when first-degree relatives are unavailable or unwilling to consider screening for the disease.

Genetic testing in individuals with an equivocal clinical diagnosis (e.g. athletes and hypertensives), should only be performed after detailed clinical and family assessment by teams experienced in the diagnosis and management of cardiomyopathies as the absence of a sarcomere mutation does not exclude familial HCM and variants of uncertain significance are difficult to interpret.

Genetic analysis of post-mortem tissue or DNA samples can be valuable in the assessment of surviving relatives, but must be interpreted in the light of detailed post-mortem examination of the heart and in accordance with conventional rules for assigning pathogenicity to genetic variants.

**Recommendations on genetic testing in probands**

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Class†</th>
<th>Level‡</th>
<th>Ref.††</th>
</tr>
</thead>
<tbody>
<tr>
<td>Genetic testing is recommended in patients fulfilling diagnostic criteria for HCM, when it enables cascade genetic screening of their relatives.</td>
<td>I</td>
<td>B</td>
<td>24,175, 178–180</td>
</tr>
<tr>
<td>It is recommended that genetic testing be performed in certificed diagnostic laboratories with expertise in the interpretation of cardiomyopathy-related mutations.</td>
<td>I</td>
<td>C</td>
<td>168,172,183</td>
</tr>
<tr>
<td>In the presence of symptoms and signs of disease suggestive of specific causes of HCM, genetic testing is recommended to confirm the diagnosis.</td>
<td>I</td>
<td>B</td>
<td>36–40, 43–46,67</td>
</tr>
<tr>
<td>Genetic testing in patients with a borderline diagnosis of HCM should be performed only after detailed assessment by specialist teams.</td>
<td>IIa</td>
<td>C</td>
<td>168</td>
</tr>
<tr>
<td>Post-mortem genetic analysis of stored tissue or DNA should be considered in deceased patients with pathologically confirmed HCM, to enable cascade genetic screening of their relatives.</td>
<td>IIa</td>
<td>C</td>
<td>181,182</td>
</tr>
</tbody>
</table>

DNA = deoxyribonucleic acid; HCM = hypertrophic cardiomyopathy.

†Class of recommendation.

‡Level of evidence.

††Reference(s) supporting recommendations.

§Borderline: left ventricular wall thickness 12–13 mm in adults; left ventricular hypertrophy in the presence of hypertension, athletic training, valve disease.

### 6.4 Genetic and clinical screening of relatives

The legal framework for informing relatives about the presence of a potentially inheritable condition in their family varies considerably around the world. In most countries it is the proband (usually the first person in the family to be diagnosed) and not the clinician, who must inform relatives and invite them for screening on behalf of the healthcare system. An information letter is sometimes provided to the patient to help this process. Since most relatives have no symptoms at initial clinical screening, it is important that they are provided with information about the consequences of a diagnosis for life insurance, pension, occupation, sporting activities, and eligibility for fostering and adoption before they are tested.

#### 6.4.1 Families with definite disease causing genetic mutations

When a definite causative genetic mutation is identified in a patient, his or her relatives should first be genetically tested, and then clinically evaluated if they are found to carry the same mutation (Figure 4).

Economic decision models have compared the cost-effectiveness of molecular screening to clinical screening alone and have shown that the combination of genetic testing and clinical screening identifies more individuals at risk of developing the disease and allows a greater number to be discharged from follow-up. For this reason, cascade genetic testing can be offered to all relatives when a definite mutation is identified in the proband. When the mutation is absent, relatives should be discharged from clinic but advised to seek re-assessment if they develop symptoms or if new clinically relevant data emerge in the family. A different approach may be considered in children, to take into account issues of consent and the long-term implications of a positive genetic test. If requested by the parents or legal guardian, clinical evaluation may precede or be substituted for genetic evaluation when this has been agreed to be in the best interests of the child.

#### 6.4.2 Families without definite disease causing genetic mutations

First-degree adult relatives should be offered clinical screening with an ECG and echocardiogram when genetic testing is not performed in the proband, or when genetic analysis fails to identify a definite mutation or reveals one or more genetic variants of unknown significance (Figure 4).

Importantly, the phenomenon of age-related penetrance means that a normal clinical evaluation does not exclude the possibility of disease development in the future; first-degree relatives should therefore be offered repeat assessment. The frequency of clinical screening in the absence of a genetic diagnosis should be guided by the age of onset and severity of cardiomyopathy within the family (e.g. the occurrence of multiple and early sudden deaths) and active participation in competitive sport. Individuals who have non-diagnostic clinical features consistent with early disease should be seen initially at intervals of 6–12 months and then less frequently if there is no progression. All relatives who complain of new cardiovascular symptoms should be re-evaluated promptly.
**6.5 Clinical and genetic screening of children**

Clinical and genetic testing of children should be guided by the best interests of each child in accordance with international standards for good practice. Potential benefits of screening in childhood include reduction of uncertainty and anxiety, psychological adjustment, the opportunity to make realistic life plans, and targeted clinical surveillance. Potential harm includes increased ambiguity if a specific phenotype cannot be predicted, alteration of self-image, distortion of perception of the child by parents and other responsible adults such as teachers, increased anxiety and guilt, and compromised life insurance prospects.

The guiding principle is that a genetic or a clinical test in a child should have an impact on management, lifestyle and further clinical screening.

Prospective clinical data on children with disease causing sarcomere protein gene mutations are limited, but best evidence suggests that clinically important events in asymptomatic children are rare before puberty. The consensus view of the committee preparing these Guidelines is that clinical and/or genetic screening should be considered from the age of 10 years onwards. Clinical or genetic testing at a younger age may be appropriate in families with early-onset disorders (for example, disorders of the MAPK pathway, inherited errors of metabolism or multiple sarcomere mutations), when there is a malignant family history in childhood and when children have cardiac symptoms or are involved in particularly demanding physical activity.

---

**Figure 4** Flow chart for the genetic and clinical screening of probands and relatives.

---

**Table 4 recommendations for genetic and clinical testing of adult relatives**

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Class</th>
<th>Level</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cascade genetic screening, after pre-test counselling, is recommended in first-degree adult relatives of patients with a definite disease-causing mutation.</td>
<td>I</td>
<td>B</td>
<td>24,175,178–180</td>
</tr>
<tr>
<td>Clinical evaluation, employing ECG and echocardiography and long-term follow-up, is recommended in first-degree relatives who have the same definite disease-causing mutation as the proband.</td>
<td>I</td>
<td>C</td>
<td>168</td>
</tr>
<tr>
<td>First-degree relatives who do not have the same definite disease-causing mutation as the proband should be discharged from further follow-up but advised to seek re-assessment if they develop symptoms or when new clinically relevant data emerge in the family.</td>
<td>IIa</td>
<td>B</td>
<td>34,185,186,189</td>
</tr>
<tr>
<td>When no definite genetic mutation is identified in the proband or genetic testing is not performed, clinical evaluation with ECG and echocardiography should be considered in first-degree adult relatives and repeated every 2–5 years (or 6–12 monthly if non-diagnostic abnormalities are present).</td>
<td>IIa</td>
<td>C</td>
<td>168,185,187,188</td>
</tr>
</tbody>
</table>

**Legend**

- ECG = electrocardiogram.
- Class of recommendation.
- Level of evidence.
- Reference(s) supporting recommendations.
- Proband = usually the first family member to be diagnosed with the condition.
6.6 Follow-up of mutation carriers without a phenotype

Preliminary studies suggest that there are no major adverse psychological consequences associated with long-term clinical and genetic screening in children and adults at risk of disease development when they are managed in expert centres.\(^{189}\) There are very few data on the natural histories of individuals who carry a disease-causing mutation and have no phenotype, but recent studies suggest a benign clinical course for most clinically unaffected mutation carriers.\(^{189,192}\) The clinical significance of mild morphological and functional abnormalities is uncertain but probably minor in most cases.\(^{194–196}\) Sudden cardiac death is rare in the absence of cardiac hypertrophy and is confined mostly to isolated reports of patients with troponin T gene mutations.\(^{27,28,197,198}\) Cross-sectional studies suggest age-related increases in penetrance,\(^{30,189,199–201}\) implying that a proportion of clinically unaffected mutation carriers will develop overt cardiomyopathy later in life. Thus, precautionary long-term evaluation of normal healthy mutation carriers is recommended. Mutation carriers without disease expression on ECG or echocardiography, who wish to participate in competitive sports, should be advised on a local basis, taking into account the local legal framework, the underlying mutation and the type of sporting activity.\(^{202}\)

### Recommendations for follow-up of mutation carriers without a phenotype

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Class(^a)</th>
<th>Level(^b)</th>
<th>Ref.(^c)</th>
</tr>
</thead>
<tbody>
<tr>
<td>The children of patients with a definite disease-causing mutation should be considered for predictive genetic testing—following pre-test family counselling—when they are aged 10 or more years and this should be carried out in accordance with international guidelines for genetic testing in children.</td>
<td>IIa</td>
<td>C</td>
<td>168,190,192</td>
</tr>
<tr>
<td>In first-degree child relatives aged 10 or more years, in whom the genetic status is unknown, clinical assessment with ECG and echocardiography should be considered every 1–2 years between 10 and 20 years of age, and then every 2–5 years thereafter.</td>
<td>IIa</td>
<td>C</td>
<td>168</td>
</tr>
<tr>
<td>If requested by the parent(s) or legal representative(s), clinical assessment with ECG and echocardiography may precede or be substituted for genetic evaluation after counselling by experienced physicians and when it is agreed to be in the best interests of the child.</td>
<td>IIb</td>
<td>C</td>
<td>168</td>
</tr>
<tr>
<td>When there is a malignant family history in childhood or early-onset disease or when children have cardiac symptoms or are involved in particularly demanding physical activity, clinical or genetic testing of first-degree child relatives before the age of 10 years may be considered.</td>
<td>IIb</td>
<td>C</td>
<td>168</td>
</tr>
</tbody>
</table>

ECG = electrocardiogram.

\(^{a}\)Class of recommendation.

\(^{b}\)Level of evidence.

\(^{c}\)Reference(s) supporting recommendations.

6.7 Pre-implantation and pre-natal genetic testing

(See also section 11.4)

Pre-natal genetic diagnosis can be performed at the beginning of pregnancy using chorionic villus sampling or amniocentesis, but the procedure is not legal in some European countries and is restricted to severe and untreatable diseases in others. Given the considerable variability in the phenotypic expression of HCM and its often benign natural history, pre-natal genetic diagnosis of HCM will rarely be appropriate.\(^{168,203}\) Alternative options to pre-natal diagnosis can be discussed, such as adoption, artificial insemination using donated gametes, and pre-implantation genetic diagnosis.\(^{168}\) Use of foetal echocardiography to detect early disease is not recommended since the probability of cardiac expression in the foetus is extremely low, with the exception of some syndromic and metabolic disorders.

7. Delivery of care

Hypertrophic cardiomyopathy is an ‘umbrella’ term that encompasses a diverse and complex spectrum of genetic and acquired diseases. As a consequence, the diagnosis and management of patients with HCM requires a range of skills and competencies. In some healthcare systems, a ‘hub and spoke’ model—in which specialist services are concentrated in a small number of central facilities, with less specialist aspects of care provided by district cardiology services—may be the most effective way of providing the necessary range of skills.\(^{148,204}\) In other systems, a less centralized approach may be more practical. Whatever the model used, all patients and families should be managed in accordance with the same internationally agreed standards.

Whilst it is not the remit of this task force to describe in detail systems of care for patients with HCM, adherence to a standard of
care is essential if the recommendations of these Guidelines are to be implemented effectively.

### Recommendations on delivery of care

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Class&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Level&lt;sup&gt;b&lt;/sup&gt;</th>
<th>Ref.&lt;sup&gt;c&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>It is recommended that individuals who have an uncertain diagnosis, severe symptoms or increased risk for disease-related complications, be referred to specialist teams for further investigation and management.</td>
<td>I</td>
<td>C</td>
<td>148,149</td>
</tr>
<tr>
<td>Irrespective of symptom status, regular clinical surveillance of patients—and, when appropriate, their first-degree relatives—is recommended.</td>
<td>I</td>
<td>C</td>
<td>168</td>
</tr>
<tr>
<td>In all cases of HCM, clinicians should consider evaluation of patients in centres of multidisciplinary teams, with expertise in the diagnosis, genetics, risk stratification and management of heart muscle disease.</td>
<td>IIa</td>
<td>C</td>
<td>148,149</td>
</tr>
</tbody>
</table>

HCM = hypertrophic cardiomyopathy.  
<sup>a</sup>Class of recommendation.  
<sup>b</sup>Level of evidence.  
<sup>c</sup>Reference(s) supporting recommendations.

### 7.1 Education and training

With advancing knowledge and greater public awareness of inherited cardiac conditions, the demand for specialist cardiomyopathy services will grow. National societies and healthcare providers should ensure that there is a workforce with the necessary skills to fulfil this need, and provide sufficient educational resources to improve and maintain competencies for all professional groups involved in the care of patients with HCM. National and international societies should also develop registries and care networks for patients with cardiomyopathies.

### 8. Assessment of symptoms

Most people with HCM are asymptomatic and have a normal lifespan but some develop symptoms, often many years after the appearance of ECG or echocardiographic evidence of LVH. In infants, symptoms and signs of heart failure include tachypnoea, poor feeding, excessive sweating and failure to thrive. Older children, adolescents and adults complain of fatigue and dyspnoea as well as chest pain, palpitations and syncope. Systematic 2D and Doppler echocardiography and ambulatory ECG monitoring are usually sufficient to determine the most likely cause of symptoms. Assessment of LVOTO as outlined in section 5.4 should be part of the routine evaluation of all symptomatic patients.

#### 8.1 Chest pain

Many patients complain of chest pain at rest or on exertion. Pain may also be precipitated by large meals or alcohol. The causes of chest pain include myocardial ischaemia due to microvascular dysfunction, increased LV wall stress and LVOTO. Congenital coronary artery anomalies, including tunnelled left anterior descending artery or atherosclerotic coronary artery disease, may also be responsible. Resting ECG abnormalities and a high prevalence of perfusion abnormalities on nuclear imaging and CMR mean that these techniques are of limited use in differentiating obstructive coronary disease from other causes of chest pain and in determining pre-test probability of coronary disease in patients with HCM. Patients with typical angina on exertion should be considered for invasive or CT coronary angiography on the basis of their symptoms, age, gender and atherosclerosis risk factors, as outlined in existing ESC Guidelines. Coronary angiography is recommended in adult survivors of cardiac arrest, in patients with sustained ventricular arrhythmia and in symptomatic patients with previous coronary revascularization procedures. Invasive or CT coronary angiography should be considered before septal reduction therapy in all patients aged 40 years or more, irrespective of the presence of typical angina.

### Recommendations on coronary angiography

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Class&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Level&lt;sup&gt;b&lt;/sup&gt;</th>
<th>Ref.&lt;sup&gt;c&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Invasive coronary angiography is recommended in adult survivors of cardiac arrest, in patients with sustained ventricular tachyarrhythmia and in patients with severe stable angina (Canadian Cardiovascular Society (CCS) Class ≥3).</td>
<td>I</td>
<td>C</td>
<td>219</td>
</tr>
<tr>
<td>Invasive or CT coronary angiography should be considered in patients with typical exertional chest pain (CCS Class &lt;3) who have an intermediate pre-test probability of atherosclerotic coronary artery disease based on age, gender and risk factors for atherosclerosis, or a history of coronary revascularization.</td>
<td>IIa</td>
<td>C</td>
<td>159,218</td>
</tr>
<tr>
<td>In all patients aged 40 years or more, invasive or CT coronary angiography should be considered before septal reduction therapy, irrespective of the presence of typical exertional chest pain.</td>
<td>IIa</td>
<td>C</td>
<td>220,221</td>
</tr>
</tbody>
</table>

CT = computed tomography; CCS = Canadian Cardiovascular Society  
<sup>a</sup>Class of recommendation.  
<sup>b</sup>Level of evidence.  
<sup>c</sup>Reference(s) supporting recommendations.

#### 8.2 Heart failure

Symptoms of chronic heart failure are frequent, but the clinical profile of advanced heart failure varies between patients. In some, heart failure is associated with diastolic dysfunction with preserved EF and small LV size; in others, symptoms are caused by systolic left ventricular dysfunction or LVOTO (with or without mitral insufficiency). Atrial fibrillation can complicate any of these scenarios and exacerbate symptoms. Recognition of the heterogeneous pathophysiology of heart failure in HCM is important because it influences management.
In most patients, there is a life-long process of progressive and adverse cardiac remodelling, characterized by myocardial fibrosis and wall thinning. In the early stages of this process, patients are often asymptomatic, and conventional non-invasive indices of cardiac performance are within the normal range. As the disease progresses, there is a decline in LV diastolic and systolic function, associated with either mild-to-moderate LV dilation, decreased LV wall thickness, and a fall in LV EF (sometimes referred to as the ‘burnt-out’ or hypokinetic dilated phase) or severe LV diastolic dysfunction, accompanied by marked atrial dilation with little or no LV dilation (the ‘restrictive’ phenotype). Mitral and tricuspid regurgitation and moderate-to-severe pulmonary hypertension are often present in these advanced stages.

Presentation with acute heart failure is uncommon, but this can be precipitated by arrhythmias [AF, supraventricular tachycardia (SVT) or sustained ventricular tachycardia (VT)], acute mitral regurgitation (e.g. chordal rupture or infective endocarditis), myocardial ischaemia or sustained ventricular tachycardia (VT), acute mitral regurgitation (e.g. chordal rupture or infective endocarditis), myocardial ischaemia and infarction, and comorbidity (e.g. anaemia or hyperthyroidism).

### 8.2.1 Invasive pressure studies

Non-invasive cardiac imaging has largely replaced cardiac catheterization in the routine assessment of cardiac function. Invasive measurement of intra-cardiac pressures may be appropriate when non-invasive cardiac imaging is insufficient to assess the severity of LVOTO and when planning invasive therapy (e.g. treatment of valve disease) and cardiac transplantation.

#### Recommendations on invasive haemodynamic studies

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Class</th>
<th>Level</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardiac catheterization—to evaluate right and left heart function and pulmonary arterial resistance—is recommended in patients being considered for heart transplantation or mechanical circulatory support.</td>
<td>I</td>
<td>B</td>
<td>227–229</td>
</tr>
<tr>
<td>In symptomatic patients with inconclusive, non-invasive cardiac imaging, left and right heart catheterization may be considered, to assess the severity of LVOTO and to measure LV filling pressures.</td>
<td>IIb</td>
<td>C</td>
<td>230</td>
</tr>
</tbody>
</table>

LV = left ventricular; LVOTO = left ventricular outflow tract obstruction.

### 8.2.2 Cardiopulmonary exercise testing

When performed in experienced laboratories, cardiopulmonary exercise testing, with simultaneous measurement of respiratory gases, provides objective information about the severity of functional limitation and its mechanisms. It may be helpful in differentiating HCM from physiological ventricular hypertrophy in athletes and can provide diagnostic clues, such as a disproportionate reduction in peak oxygen consumption and low anaerobic threshold in patients with metabolic disorders. When facilities are available, cardiopulmonary exercise testing, with simultaneous measurement of respiratory gases, should be considered at the initial clinical evaluation, when patients report a change in symptoms, and when considering invasive LV outflow tract gradient reduction.

Cardiopulmonary exercise testing is recommended in all patients being considered for cardiac transplantation.

When cardiopulmonary exercise testing is unavailable, conventional treadmill- or bicycle ergometry, with simultaneous electrocardiography, can be used as an alternative. Irrespective of the method of exercise testing, measurement of blood pressure during exercise is recommended, using a standard sphygmomanometer, in order to determine the change in systolic blood pressure that may provide prognostic information (See 9.5: Sudden cardiac death).

#### Recommendations on cardiopulmonary exercise testing

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Class</th>
<th>Level</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardiopulmonary exercise testing, with simultaneous measurement of respiratory gases, is recommended in severely symptomatic patients with systolic and/or diastolic LV dysfunction being evaluated for heart transplantation or mechanical support.</td>
<td>I</td>
<td>B</td>
<td>233,238</td>
</tr>
<tr>
<td>Irrespective of symptoms, cardiopulmonary exercise testing with simultaneous measurement of respiratory gases (or standard treadmill or bicycle ergometry when unavailable) should be considered to assess the severity and mechanism of exercise intolerance and change in systolic blood pressure.</td>
<td>IIa</td>
<td>B</td>
<td>233,235–237</td>
</tr>
<tr>
<td>Cardiopulmonary exercise testing, with simultaneous measurement of respiratory gases (or standard treadmill or bicycle ergometry when unavailable), should be considered in symptomatic patients undergoing septal alcohol ablation and septal myectomy to determine the severity of exercise limitation.</td>
<td>IIa</td>
<td>C</td>
<td>233–235</td>
</tr>
</tbody>
</table>

*a Class of recommendation.

*b Level of evidence.

*c Reference(s) supporting recommendations.

LV = left ventricular.

### 8.3 Syncope

Causes of syncope in HCM include hypovolaemia, complete heart block, sinus node dysfunction, sustained ventricular tachycardia, LVOTO, and abnormal vascular reflexes. Occasionally atrial arrhythmias with fast ventricular response can precipitate syncope, particularly in individuals with preserved atrial function and high filling pressures. There can be more than one reason why patients with HCM lose consciousness, including co-morbidities such as epilepsy and diabetes.

Syncope after prolonged standing in a hot environment, or during the postprandial absorptive state, is suggestive of neurally mediated (reflex) syncope, particularly when it is associated with nausea and vomiting. Syncope during exertion, or immediately following palpitation or chest pain, suggests a cardiac mechanism.

Provocable
obstruction should be excluded when patients experience recurrent effort syncope in similar circumstances—for example, when hurrying upstairs or straining. Ventricular arrhythmias are an uncommon cause of syncope, but should be suspected after an unheralded episode, particularly when it occurs at rest or on minimal exertion.

As unexplained non-vasovagal syncope is a risk factor for sudden cardiac death, particularly when it occurs in young patients in close temporal proximity to their first evaluation, treatment with a prophylactic implantable cardioverter defibrillator (ICD) may be appropriate in individuals with other features indicative of high sudden death risk, even if the mechanism of syncope is undetermined at the end of a complete work-up. The fact that syncope may be caused by mechanisms other than ventricular arrhythmia means that patients may remain at risk of recurrent syncope after ICD implantation.

Patients with syncope should undergo 12-lead ECG, standard upright exercise test and 48-hour ambulatory ECG monitoring and, if a bradyarrhythmia is identified, it should be treated in accordance with current ESC Guidelines on cardiac pacing. Exercise stress echocardiography should be considered, particularly in patients with exertional or postural syncope, to detect provokable LVOTO. In patients with recurrent episodes of unexplained syncope, who are at low risk of SCD, an implantable loop recorder (ILR) should be considered. There are few data on tilt testing in patients with HCM, but a high rate of positive tests in patients with documented persistent or recurrent supraventricular tachycardia (atrial flutter, atrial tachycardia, atrioventricular nodal re-entry tachycardia, accessory atrioventricular pathway mediated tachycardias) and in patients who have evidence from other non-invasive tests, suggestive of either sino-atrial disease or AV block. Electrophysiological studies are also indicated when patients have ventricular pre-excitation, to identify and treat an ablatable substrate. Invasive EPS may be considered in selected patients with documented, symptomatic, monomorphic, sustained (> 30 s) ventricular tachycardia, to identify and treat an ablatable arrhythmia substrate.

### 8.5 Role of electrophysiological testing

The routine use of electrophysiological studies (EPS) in patients with syncope or symptoms suggestive of arrhythmia is not recommended. EPS are indicated in patients with persistent or recurrent supraventricular tachycardia (atrial flutter, atrial tachycardia, atrioventricular nodal re-entry tachycardia, accessory atrioventricular pathway mediated tachycardias) and in patients with evidence from other non-invasive tests, suggestive of either sino-atrial disease or AV block. Electrophysiological studies are also indicated when patients have ventricular pre-excitation, to identify and treat an ablatable substrate. Invasive EPS may be considered in selected patients with documented, symptomatic, monomorphic, sustained (> 30 s) ventricular tachycardia, to identify and treat an ablatable arrhythmia substrate.
9. Management of symptoms and complications

In the absence of large randomized trials, pharmacological therapy is administered on an empirical basis to improve functional capacity, reduce symptoms and prevent disease progression. In symptomatic patients with LVOTO, the aim is to improve symptoms by using drugs, surgery, alcohol ablation or pacing. Therapy in symptomatic patients without LVOTO focuses on management of arrhythmia, reduction of LV filling pressures, and treatment of angina. Patients with progressive LV systolic or diastolic dysfunction refractory to medical reduction of LV filling pressures, and treatment of angina. Patients with progressive LV systolic or diastolic dysfunction refractory to medical treatment may be candidates for cardiac transplantation.

9.1 Left ventricular outflow tract obstruction

By convention, LVOTO is defined as a peak instantaneous Doppler LV outflow tract gradient of ≥30 mm Hg, but the threshold for invasive treatment is usually considered to be ≥50 mm Hg.

Most patients with a maximum resting or provoked LV outflow tract gradient <50 mm Hg should be managed in accordance with the recommendations for non-obstructive HCM but, in a very small number of selected cases with LV outflow tract gradients between 30 and 50 mm Hg and no other obvious cause of symptoms, invasive gradient reduction may be considered, acknowledging that data covering this group are lacking.

9.1.1 General measures

All patients with LVOTO should avoid dehydration and excess alcohol consumption, and weight loss should be encouraged. Arterial and venous dilators, including nitrates and phosphodiesterase type 5 inhibitors, can exacerbate LVOTO and should be avoided if possible (see also management of hypertension, section 12.2). New-onset or poorly controlled AF can exacerbate symptoms caused by LVOTO and should be managed by prompt restoration of sinus rhythm or ventricular rate control. Digoxin should be avoided in patients with LVOTO because of its positive inotropic effects.

Recommendations for treatment of left ventricular outflow tract obstruction: general measures

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Class*</th>
<th>Level†</th>
<th>Ref.‡</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arterial and venous dilators, including nitrates and phosphodiesterase type 5 inhibitors, should be avoided if possible in patients with resting or provokable LVOTO.</td>
<td>IIa</td>
<td>C</td>
<td>258,260</td>
</tr>
<tr>
<td>Restoration of sinus rhythm or appropriate rate control should be considered before considering invasive therapies in patients with new-onset or poorly controlled atrial fibrillation.</td>
<td>IIa</td>
<td>C</td>
<td>261,262</td>
</tr>
<tr>
<td>Digoxin is not recommended in patients with resting or provokable LVOTO.</td>
<td>III</td>
<td>C</td>
<td>259</td>
</tr>
</tbody>
</table>

LVOTO = left ventricular outflow tract obstruction.

*Class of recommendation.
†Level of evidence.
‡Reference(s) supporting recommendations.

9.1.2 Drug therapy

By consensus, patients with symptomatic LVOTO are treated initially with non-vasodilating β-blockers titrated to maximum tolerated dose, but there are very few studies comparing individual β-blockers. Small and mostly retrospective studies suggest that oral propranolol can abolish or reduce resting and provokable LVOTO and provide symptomatic benefit. One study has shown improved exercise tolerance and suppression of supraventricular and ventricular arrhythmias in patients treated with sotalol.

If β-blockers alone are ineffective, disopyramide (when available), titrated up to a maximum tolerated dose (usually 400–600 mg/day), may be added. This Class IA anti-arrhythmic drug can abolish basal LV outflow pressure gradients and improve exercise tolerance and functional capacity without proarrhythmic effects or an increased risk of sudden cardiac death. Dose-limiting anti-cholinergic side-effects include dry eyes and mouth, urinary hesitancy or retention, and constipation. The QTc interval should be monitored during dose up-titration and the dose reduced if it exceeds 480 ms. Disopyramide should be avoided in patients with glaucoma, in men with prostatism, and in patients taking other drugs that prolong the QT interval, such as amiodarone and sotalol. Disopyramide may be used in combination with verapamil. Disopyramide should be used cautiously in patients with— or prone to—AF in whom drug-induced enhancement of AV conduction can increase the ventricular rate.

Verapamil (starting dose 40 mg three times daily to maximum 480 mg daily) can be used when β-blockers are contraindicated or ineffective, but close monitoring is required in patients with severe obstruction (>100 mm Hg) or elevated pulmonary artery systolic pressures, as it can provoke pulmonary oedema. Short-term oral administration may increase exercise capacity, improve symptoms and normalize or improve LV diastolic filling without altering systolic function. Similar findings have been demonstrated for diltiazem (starting dose 60 mg three times daily to maximum 360 mg daily) and it should be considered in patients who are intolerant- or have contraindications to β-blockers and verapamil. Nifedipine and other dihydropyridine calcium antagonists are not recommended for the treatment of LVOTO.

Low-dose loop or thiazide diuretics may be used cautiously to improve dyspnoea associated with LVOTO, but it is important to avoid hypovolaemia.

Beta-blockers should be considered in neonates and children with LVOTO and limited data on verapamil suggest that it can also be used safely in children. There are no data on which to make specific recommendations for disopyramide therapy in children. Medical therapy may be considered in asymptomatic or mildly symptomatic adolescents and adults who have a resting or provoked LVOTO and left atrial enlargement.

Rarely, patients with severe provokable LVOTO can present with hypertension and pulmonary oedema that mimics acute myocardial ischaemia. Recognition of this scenario is important, as the use of vasodilators and positive inotropes in this setting can be life-threatening. Treatment should instead consist of oral or iv. β-blockers and vasoconstrictors (e.g. phenylephrine, metaraminol and norepinephrine).
### Recommendations on medical treatment of LVOTO

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Class</th>
<th>Level</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-vasodilating b-blockers, titrated to maximum tolerated dose, are recommended as first-line therapy to improve symptoms in patients with resting or provoked LVOTO.</td>
<td>I</td>
<td>B</td>
<td>263,265, 267,268</td>
</tr>
<tr>
<td>Verapamil, titrated to maximum tolerated dose, is recommended to improve symptoms in patients with resting or provoked LVOTO, who are intolerant or have contraindications to b-blockers.</td>
<td>I</td>
<td>B</td>
<td>268,270–274</td>
</tr>
<tr>
<td>Disopyramide, titrated to maximum tolerated dose, is recommended in addition to a b-blocker (or, if this is not possible, with verapamil) to improve symptoms in patients with resting or provoked LVOTO.</td>
<td>I</td>
<td>B</td>
<td>267,268</td>
</tr>
<tr>
<td>Disopyramide, titrated to maximum tolerated dose, may be considered as monotherapy to improve symptoms in patients with resting or provoked LVOTO (exercise or Valsalva manoeuvre) taking caution in patients with—or prone to—AF, in whom it can increase ventricular rate response.</td>
<td>IIb</td>
<td>C</td>
<td>267</td>
</tr>
<tr>
<td>b-Blockers or verapamil may be considered in children and asymptomatic adults with resting or provoked LVOTO, to reduce left ventricular pressures.</td>
<td>IIb</td>
<td>C</td>
<td>272</td>
</tr>
<tr>
<td>Low-dose loop- or thiazide diuretics may be used with caution in symptomatic LVOTO, to improve exertional dyspnoea.</td>
<td>IIb</td>
<td>C</td>
<td>272</td>
</tr>
<tr>
<td>Diltiazem, titrated to maximum tolerated dose, should be considered in symptomatic patients with resting or provoked LVOTO, who are intolerant or have contraindications to b-blockers and verapamil, to improve symptoms.</td>
<td>IIa</td>
<td>C</td>
<td>274</td>
</tr>
<tr>
<td>Oral or i.v. b-blockers and vasoconstrictors should be considered in patients with severe provokable LVOTO presenting with hypotension and pulmonary oedema.</td>
<td>IIa</td>
<td>C</td>
<td>260</td>
</tr>
</tbody>
</table>

LVOTO = left ventricular outflow tract obstruction.  
*Class of recommendation.  
Level of evidence.  
Reference(s) supporting recommendations.  
Provocation with Valsalva manoeuvre, upright exercise or oral nitrates if unable to exercise.  
QTc interval should be monitored during up-titrations of disopyramide and the dose reduced if it exceeds 480 ms.

### 9.1.3 Invasive treatment of left ventricular outflow tract obstruction

There are no data to support the use of invasive procedures to reduce LV outflow obstruction in asymptomatic patients, regardless of its severity.

Invasive treatment to reduce LVOTO should be considered in patients with an LVOTO gradient ≥50 mm Hg, moderate-to-severe symptoms (New York Heart Association (NYHA) functional Class III–IV) and/or recurrent exertional syncope in spite of maximally tolerated drug therapy. In some centres, invasive therapy is also considered in patients with mild symptoms (NYHA Class II) who have a resting or maximum provoked gradient of ≥50 mm Hg (exercise or Valsalva) and moderate-to-severe SAM related mitral regurgitation, AF, or moderate-to-severe left atrial dilation but there are few data supporting this practice.

#### 9.1.3.1 Surgery

The most commonly performed surgical procedure used to treat LVOTO is ventricular septal myectomy (Morrow procedure), in which a rectangular trough that extends distally to beyond the point of the mitral leaflet–septal contact is created in the basal septum below the aortic valve. This abolishes or substantially reduces LV outflow tract gradients in over 90% of cases, reduces SAM-related mitral regurgitation, and improves exercise capacity and symptoms. Long-term symptomatic benefit is achieved in 70–80% of patients with a long-term survival comparable to that of the general population. Pre-operative determinants of a good long-term outcome are age <50 years, left atrial size <46 mm, absence of atrial fibrillation and male gender.

The main surgical complications are AV nodal block, ventricular septal defect and aortic regurgitation (AR), but these are uncommon in experienced centres using intraoperative TOE guidance. When there is co-existing mid-cavity obstruction, the standard myectomy can be extended distally into the mid-ventricle around the base of the papillary muscles, but data on the efficacy and long-term outcomes of this approach are limited.

Concomitant mitral valve surgery is required in 11–20% of patients undergoing myectomy. In patients with marked mitral leaflet elongation and/or moderate-to-severe mitral regurgitation, septal myectomy can be combined with one of several adjunctive procedures, including mitral valve replacement, posterior-superior realignment of the papillary muscles, partial excision and mobilization of papillary muscles, anterior mitral leaflet plication, and anterior leaflet extension using a glutaraldehyde-treated pericardial patch that stiffens the mid-porion of the leaflet. An elongated anterior mitral leaflet favours mitral valve repair instead of replacement.

Surgical mortality for myectomy with mitral intervention is around 3–4%. Concomitant mitral valve surgery is required in 11–20% of patients undergoing myectomy. In patients with marked mitral leaflet elongation and/or moderate-to-severe mitral regurgitation, septal myectomy can be combined with one of several adjunctive procedures, including mitral valve replacement, posterior-superior realignment of the papillary muscles, partial excision and mobilization of papillary muscles, anterior mitral leaflet plication, and anterior leaflet extension using a glutaraldehyde-treated pericardial patch that stiffens the mid-porion of the leaflet. An elongated anterior mitral leaflet favours mitral valve repair instead of replacement.

Surgical mortality for myectomy with mitral intervention is around 3–4%. Concomitant mitral valve surgery is required in 11–20% of patients undergoing myectomy. In patients with marked mitral leaflet elongation and/or moderate-to-severe mitral regurgitation, septal myectomy can be combined with one of several adjunctive procedures, including mitral valve replacement, posterior-superior realignment of the papillary muscles, partial excision and mobilization of papillary muscles, anterior mitral leaflet plication, and anterior leaflet extension using a glutaraldehyde-treated pericardial patch that stiffens the mid-porion of the leaflet. An elongated anterior mitral leaflet favours mitral valve repair instead of replacement.

#### 9.1.3.2 Septal alcohol ablation

In experienced centres, selective injection of alcohol into a septal perforator artery (or sometimes other branches of the left anterior descending coronary artery) to create a localized septal scar has outcomes similar to surgery in terms of gradient reduction, symptom improvement and exercise capacity. The main non-fatal complication is AV block in 7–20% of patients and the procedural mortality is similar to isolated myectomy.
Due to the variability of the septal blood supply, myocardial contrast echocardiography is essential prior to alcohol injection. If the contrast agent cannot be localized exclusively to the basal septum at and adjacent to the point of mitral-septal contact, the procedure should be abandoned.\textsuperscript{111–113}

Injection of large volumes of alcohol in multiple septal branches—with the aim of gradient reduction in the catheter laboratory—is not recommended, as it is associated with a high risk of complications and arrhythmic events.\textsuperscript{304}

Alternative methods have been reported in small numbers of patients, including non-alcohol septal embolisation techniques (coils,\textsuperscript{305,306} polyvinyl alcohol foam particles,\textsuperscript{307} cyanoacrylate\textsuperscript{308}) and direct endocavitary ablation (radiofrequency, cryotherapy).\textsuperscript{309,310} These alternative methods have not been directly compared with other septal reduction therapies and long-term outcome/safety data are not available.

9.1.3.3 Surgery vs. alcohol ablation

Experienced multidisciplinary teams should assess all patients before intervention.

The choice of therapy should be based on a systematic assessment of the mitral valve and septal anatomy that includes deliberate exclusion of other LV outflow tract and mitral valve abnormalities requiring surgical treatment. A summary of the key points in pre-operative assessment is shown in Figure 5. Septal ablation may be less effective in patients with extensive septal scarring on CMR and in patients with very severe hypertrophy (≥30 mm), but systematic data are lacking. In general, the risk of ventricular septal defect following septal alcohol ablation and septal myectomy is higher in patients with mild hypertrophy (<16 mm) at the point of the mitral leaflet–septal contact. In such cases, alternatives such as dual chamber pacing (see 9.1.3.5: Dual chamber pacing) or mitral valve repair/replacement may be considered.

There are no randomized trials comparing surgery and septal alcohol ablation (SAA), but several meta-analyses have shown that both procedures improve functional status with a similar procedural mortality.\textsuperscript{291–294} Septal alcohol ablation is associated with a higher risk of AV block, requiring permanent pacemaker implantation and larger residual LV outflow tract gradients.\textsuperscript{311–314} In contrast to myectomy, most patients develop right- rather than left bundle branch block after SAA. The risk of AV block following surgery and alcohol ablation is highest in patients with pre-existing conduction disease, and prophylactic permanent pacing before intervention has been advocated.\textsuperscript{315}

The operative mortality of septal myectomy in children is <2% in experienced centres.\textsuperscript{286} Recurrence of LVOTO requiring re-operation is rare, except in infants and neonates, due to technical limitations of resection and progression of myocardial hypertrophy. Septal alcohol ablation is controversial in children, adolescents and young adults because there are no long-term data on the late effects of a myocardial scar in these groups, and because the technical difficulties and potential hazards of the procedure in smaller children and infants are greater.

9.1.3.4 Minimum activity requirements

As with other invasive procedures, the results of surgery and alcohol ablation are likely to be better in centres that perform large numbers of procedures. In the absence of specific data, recommendations for the number of interventions per centre and operator are extrapolated from other scenarios. A minimum caseload of 10 SAA and 10 septal myectomies per operator per year is reasonable. More than

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Class\textsuperscript{a}</th>
<th>Level\textsuperscript{b}</th>
<th>Ref.\textsuperscript{c}</th>
</tr>
</thead>
<tbody>
<tr>
<td>It is recommended that septal reduction therapies be performed by experienced operators, working as part of a multidisciplinary team expert in the management of HCM.</td>
<td>I</td>
<td>C</td>
<td>148,149</td>
</tr>
<tr>
<td>Septal reduction therapy to improve symptoms is recommended in patients with a resting or maximum provoked LVOTO gradient ≥50 mm Hg, who are in NYHA functional Class III–IV, despite maximum tolerated medical therapy.</td>
<td>I</td>
<td>B</td>
<td>311–314</td>
</tr>
<tr>
<td>Septal reduction therapy should be considered in patients with recent exertional syncope caused by a resting or maximum provoked LVOTO gradient ≥50 mm Hg despite optimal medical therapy.</td>
<td>IIa</td>
<td>C</td>
<td>240,316</td>
</tr>
<tr>
<td>Septal myectomy, rather than SAA, is recommended in patients with an indication for septal reduction therapy and other lesions requiring surgical intervention (e.g. mitral valve repair/replacement, papillary muscle intervention).</td>
<td>I</td>
<td>C</td>
<td>295</td>
</tr>
<tr>
<td>Mitral valve repair or replacement should be considered in symptomatic patients with a resting or maximum provoked LVOTO gradient ≥50 mm Hg and moderate-to-severe mitral regurgitation not caused by SAM of the mitral valve alone.</td>
<td>IIa</td>
<td>C</td>
<td>291–294</td>
</tr>
<tr>
<td>Mitral valve repair or replacement may be considered in patients with a resting or maximum provoked LVOTO gradient ≥50 mm Hg and a maximum septal thickness ≤16 mm at the point of the mitral leaflet–septal contact or when there is moderate-to-severe mitral regurgitation following isolated myectomy.</td>
<td>IIb</td>
<td>C</td>
<td>296,317</td>
</tr>
</tbody>
</table>

AF = atrial fibrillation; HCM = hypertrophic cardiomyopathy; LA = left atrium; LVOTO = left ventricular outflow tract obstruction; NYHA = New York Heart Association; SAA = septal alcohol ablation; SAM = systolic anterior motion.

\textsuperscript{a}Class of recommendation.

\textsuperscript{b}Level of evidence.

\textsuperscript{c}Reference(s) supporting recommendations.
one trained operator should be available for both procedures, to ensure the safety and sustainability of interventional programmes. National data collection and prospective registries are encouraged to monitor safety and outcomes.

Surgeons and cardiologists who perform invasive gradient reduction therapies should be trained in experienced centres and should work as part of a multidisciplinary team experienced in the management of HCM.

9.1.3.5 Dual chamber pacing

Three small, randomized, placebo-controlled studies of dual chamber pacing and several long-term observational studies have reported reductions in LV outflow tract gradients and variable improvement in symptoms and quality of life.\(^{318–322}\) In one trial, a retrospective subgroup analysis suggested that older patients (>65 years) are more likely to benefit.\(^{321}\) One study has directly compared SAA with pacing and demonstrated superior gradient reduction with ablation.\(^{323}\) A recent Cochrane review concluded that the data on the benefits of pacing are based on physiological measures and lack information on clinically relevant end-points.\(^{324}\)

Permanent AV sequential pacing with short AV interval may be considered in symptomatic adult patients who are unsuitable for—or unwilling to consider—other invasive septal reduction therapies, and in patients who have other pacing indications. Pacing parameters should be optimized to achieve maximum pre-excitation of the RV apex with minimal compromise of LV filling (typically achieved with a resting sensed AV interval of 100 ± 30 ms).\(^{325}\) To ensure complete ventricular capture during exercise, a dynamic paced AV interval should be enabled and the programmed upper rate limit should be higher than the fastest sinus rate achieved during exercise.\(^{249}\) Atrioventricular nodal ablation or modification has been advocated as a method for achieving optimal AV programming in some patients with a very short P-R interval, but this is not recommended.\(^{326}\)

Recommendations on indications for cardiac pacing in patients with obstruction

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Class(^{a})</th>
<th>Level(^{b})</th>
<th>Ref.(^{c})</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sequential AV pacing, with optimal AV interval to reduce the LV outflow tract gradient or to facilitate medical treatment with β-blockers and/or verapamil, may be considered in selected patients with resting or provokable LVOTO &gt;50 mm Hg, sinus rhythm and drug-refractory symptoms, who have contraindications for septal alcohol ablation or septal myectomy or are at high risk of developing heart block following septal alcohol ablation or septal myectomy.</td>
<td>IIb</td>
<td>C</td>
<td>268,318–322</td>
</tr>
<tr>
<td>In patients with resting or provokable LVOTO &gt;50 mm Hg, sinus rhythm and drug-refractory symptoms, in whom there is an indication for an ICD, a dual-chamber ICD (instead of a single-lead device) may be considered, to reduce the LV outflow tract gradient or to facilitate medical treatment with β-blockers and/or verapamil.</td>
<td>IIb</td>
<td>C</td>
<td>268,318–322,327</td>
</tr>
</tbody>
</table>

AV = atrioventricular; ICD = implantable cardioverter defibrillator; LVOTO = left ventricular outflow tract obstruction.

\(^{a}\)Class of recommendation.

\(^{b}\)Level of evidence.

\(^{c}\)Reference(s) supporting recommendations.

Are there alternative/additional explanations for symptoms?

- Obesity
- Respiratory disease
- Coronary artery disease
- Anaemia
- Thyroid disease
- Arrhythmias (e.g. AF)
- Drug side-effects
- Systemic disease (e.g. amyloid)
- RVOT obstruction

What is the mechanism of obstruction?

- SAM-related
- Mid-cavity
- Sub-aortic membrane
- Aortic stenosis
- Anomalous papillary muscle insertion
- Accessory mitral valve tissue

Assess mitral valve anatomy/function

- Mitral prolapse
- Other intrinsic MV abnormality

Assess distribution and severity of hypertrophy

- Minimum anterior septal thickness (mm)

Figure 5 Pre-assessment check list for patients being considered for invasive septal reduction therapies. AF = atrial fibrillation; MV = mitral valve; RVOT = right ventricular outflow tract; SAM = systolic anterior motion.
9.2 Left ventricular mid-cavity obstruction and apical aneurysms
LV mid-cavity obstruction occurs in approximately 10% of patients with HCM. Patients with mid-cavity obstruction tend to be very symptomatic and, in a number of studies, have shown an increased risk of progressive heart failure and SCD. Approximately 25% of patients also have an LV apical aneurysm which, in some series, is associated with higher cardiovascular mortality. Patients with LV mid-cavity obstruction should be treated with high dose ß-blockers, verapamil or diltiazem, but the response is often suboptimal. Small experience, mostly from single centres, suggests that mid-ventricular obstruction can be relieved by transaortic myectomy, a transapical approach or combined transaortic and transapical incisions, with good short-term outcomes.

LV apical aneurysms by themselves rarely need treatment. A few patients develop monomorphic ventricular tachycardia related to adjacent apical scarring, which may be amenable to mapping and ablation. Rarely, thrombi are present within the aneurysm and should be treated with long-term oral anticoagulation. The evidence linking aneurysms to an increased risk of sudden death is confined to small series of selected patients. Prophylactic ICD implantation is not recommended in the absence of other clinical features that suggest an increased risk of SCD (see section 9.5).

9.3 Management of symptoms in patients without left ventricular outflow tract obstruction

9.3.1 Heart failure

9.3.1.1 Drug therapy
A general approach to the management of heart failure symptoms is shown in Figure 6. In breathless patients with a normal EF and no evidence of resting or provokable LVOTO, the aim of drug therapy is to reduce LV diastolic pressures and improve LV filling by slowing the heart rate with ß-blockers, verapamil or diltiazem (ideally monitored by ambulatory ECG recording) and cautious use of loop diuretics. Restoration of sinus rhythm or ventricular rate control is essential in patients who have permanent or frequent paroxysms of AF (see Atrial tachyarrhythmia, section 9.4) but digoxin is not recommended in patients with preserved EF because of the potentially adverse effects of positive inotropic stimulation.

Very few studies have examined the effect of renin-angiotensin-aldosterone system (RAAS) inhibition in patients with HCM. In the absence of randomized trials, the benefit of RAAS inhibition on hospitalization, symptoms and mortality is assumed, and it is recommended that patients with reduced EF and heart failure symptoms should be treated with diuretics, ß-blockers, angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARB) and mineralocorticoid receptor antagonists (MRA) in line with the ESC Guidelines for the management of chronic heart failure. An EF of <50% is recommended as the threshold for considering therapy with RAAS inhibitors because of the preservation of cavity size in patients with HCM and advanced systolic failure. Relatively small LV volumes also mean that some patients may be unable to tolerate high doses of vasodilators and diuretics. In the absence of significant LVOTO, digoxin (0.125 mg–0.5 mg o.d.), alone or in combination with ß-blocker, may be used to control heart rate response in patients with AF and an EF <50%.

Recommendations for patients with heart failure and preserved LV ejection fraction (≥50%)

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Class</th>
<th>Level</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>In patients in NYHA functional Class II–IV with an EF ≥50% and no evidence for resting or provokable LVOTO, ß-blockers, verapamil or diltiazem should be considered, to improve heart failure symptoms.</td>
<td>Ila</td>
<td>C</td>
<td>274,338</td>
</tr>
<tr>
<td>Low-dose loop and thiazide diuretics should be considered in patients in NYHA functional Class II–IV with an EF ≥50% and no evidence for resting or provokable LVOTO, to improve heart failure symptoms.</td>
<td>Ila</td>
<td>C</td>
<td></td>
</tr>
</tbody>
</table>

Recommendations for patients with heart failure and reduced LV ejection fraction (<50%)

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Class</th>
<th>Level</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>An ACE inhibitor (or ARB if ACE inhibitor not tolerated) should be considered, in addition to a ß-blocker, for patients without LVOTO who have an LVEF &lt;50%, to reduce the risks of HF hospitalization and premature death.</td>
<td>Ila</td>
<td>C</td>
<td>337</td>
</tr>
<tr>
<td>A ß-blocker should be considered, in addition to an ACE inhibitor (or ARB if ACE inhibitor not tolerated), for patients without LVOTO who have an LVEF &lt;50% to improve symptoms and reduce the risks of HF hospitalization and premature death.</td>
<td>Ila</td>
<td>C</td>
<td>337</td>
</tr>
<tr>
<td>Low-dose loop diuretics should be considered for symptomatic patients in NYHA functional Class II–IV with an LVEF &lt;50%, to improve symptoms and reduce the risk of HF hospitalization.</td>
<td>Ila</td>
<td>C</td>
<td>337</td>
</tr>
<tr>
<td>For all patients with persisting symptoms (NYHA functional Class II–IV) and an LVEF &lt;50%—despite treatment with an ACE inhibitor (or an ARB if an ACE inhibitor is not tolerated) and a ß-blocker—a mineralocorticoid receptor antagonist (MRA) should be considered, to reduce the risks of HF hospitalization and premature death.</td>
<td>Ila</td>
<td>C</td>
<td>337</td>
</tr>
<tr>
<td>Low-dose digoxin may be considered for patients without LVOTO who are in NYHA functional Class II–IV and have an EF &lt;50% and permanent atrial fibrillation to control heart rate response.</td>
<td>Ib</td>
<td>C</td>
<td>337</td>
</tr>
</tbody>
</table>

ACE = angiotensin-converting enzyme; ARB = angiotensin receptor blocker; EF = ejection fraction; HF = heart failure; MRA = mineralocorticoid receptor antagonist; LV = left ventricular; NYHA = New York Heart Association.

Class of recommendation.

Level of evidence.

Reference(s) supporting recommendations.

In the absence of randomized trials in HCM, the benefit on hospitalization, symptoms and mortality is assumed but unproven.
9.3.1.2 Cardiac resynchronization therapy

Regional heterogeneity of LV contraction and relaxation is common in patients with HCM and LV dyssynchrony may be a marker of poor prognosis. Case reports and one cohort study have shown that cardiac resynchronization therapy (CRT) can improve heart failure symptoms in patients with left bundle branch block (LBBB) (>120 ms) and is associated with reverse remodelling of the left atrium and LV in patients with impaired LV systolic function. In the absence of randomized trials, CRT may be considered in individual patients with refractory symptoms, LV EF <50% and LBBB (QRS duration >120 ms). For patients who have progressed to severe LV dysfunction (EF ≤35%), CRT should be in accordance with current ESC Guidelines.

### Recommendations on cardiac resynchronization therapy

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Class*</th>
<th>Levelβ</th>
<th>Ref.α</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardiac resynchronization therapy to improve symptoms may be considered in patients with HCM, maximum LVOTG &lt;30 mm Hg, drug refractory symptoms, NYHA functional Class II–IV; LVEF &lt;50% and LBBB with a QRS duration &gt;120 ms.</td>
<td>IIb</td>
<td>C</td>
<td>339</td>
</tr>
</tbody>
</table>

EF = ejection fraction; HCM = hypertrophic cardiomyopathy; LBBB = left bundle branch block; LV = left ventricular; LVOTG = left ventricular outflow tract gradient; NYHA = New York Heart Association.

*Class of recommendation.  
βLevel of evidence.  
αReference(s) supporting recommendations.

9.3.1.3 Cardiac transplantation

Orthotopic cardiac transplantation should be considered in patients with moderate-to-severe drug refractory symptoms (NYHA functional Class III–IV) and no LVOTO who meet standard eligibility criteria (see the ESC Guidelines on acute and chronic heart failure). HCM accounts for 1–5% of all cardiac transplants performed in the USA and up to 7% of patients on the heart transplantation waiting list in European centres. In adolescents and adults, end-stage HCM with LV dilation and systolic dysfunction is the most common clinical profile, with progression to intractable heart failure being more rapid in young patients. In infants, massive cardiac hypertrophy with small ventricular cavities and refractory diastolic heart failure is more typical. Around 5% of patients referred for cardiac transplantation have refractory ventricular arrhythmia, with or without heart failure symptoms. Post-transplant survival is similar to that of other non-HCM indications and superior to that of patients with ischaemic heart disease, with a lower rate of acute rejection.

### Recommendations on cardiac transplantation

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Class*</th>
<th>Levelβ</th>
<th>Ref.α</th>
</tr>
</thead>
<tbody>
<tr>
<td>Orthotopic cardiac transplantation should be considered in eligible patients who have an LVEF &lt;50% and NYHA functional Class III–IV symptoms despite optimal medical therapy or intractable ventricular arrhythmia.</td>
<td>IIa</td>
<td>B</td>
<td>340,341,343,344</td>
</tr>
<tr>
<td>Orthotopic cardiac transplantation may be considered in eligible patients with normal LVEF (≥50%) and severe drug refractory symptoms (NYHA functional Class III–IV) caused by diastolic dysfunction.</td>
<td>IIb</td>
<td>B</td>
<td>340,341,343,344</td>
</tr>
</tbody>
</table>

HF = heart failure; LVEF = left ventricular ejection fraction; NYHA = New York Heart Association.  
*Class of recommendation.  
βLevel of evidence.  
αReference(s) supporting recommendations.

9.3.1.4 Left ventricular assist devices

As there are increasing numbers of patients with end-stage heart failure and the organ donor pool remains limited, mechanical circulatory support with an LV assist device (LVAD) or biventricular assist device (BiVAD) is increasingly used as a short-term bridge to transplant, or destination therapy in individuals who are not eligible for transplantation. Left ventricular assist devices are rarely used as a bridge to orthotopic heart transplantation in patients with HCM, because their small LV cavities and restrictive LV physiology are thought to preclude device placement. However, preliminary data show that patients with HCM and end-stage heart failure may benefit from continuous axial flow LVAD therapy. In one study, right heart failure, prolonged inotropic support, and central venous catheter infections were more common in patients with HCM who were treated with LVADs, but the procedural mortality was comparable to patients with dilated cardiomyopathy and ischaemic heart disease. Further research is required in this area but continuous axial flow LVAD therapy may be an option for bridging to therapy in selected patients who are transplant candidates. There are no data on bridge-to-recovery or destination therapy in patients with HCM.

### Recommendations on left ventricular assist devices

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Class*</th>
<th>Levelβ</th>
<th>Ref.α</th>
</tr>
</thead>
<tbody>
<tr>
<td>Continuous axial flow LVAD therapy may be considered in selected patients with end-stage HF despite optimal pharmacological and device treatment, who are otherwise suitable for heart transplantation, to improve symptoms, and reduce the risk of HF hospitalization from worsening HF and premature death while awaiting a transplant.</td>
<td>IIb</td>
<td>C</td>
<td>346</td>
</tr>
</tbody>
</table>

HF = heart failure; LVAD = left ventricular assist device.  
*Class of recommendation.  
βLevel of evidence.  
αReference(s) supporting recommendations.

9.3.2 Angina

ß-Blockers or calcium antagonists should be considered in patients with exertional or prolonged episodes of angina-like pain in the absence of resting or provocable LVOTO or obstructive coronary artery disease. Both classes of drug improve diastolic function and reduce myocardial oxygen demand and, in the case of verapamil, may improve stress-induced sub-endocardial perfusion defects. In the absence of LVOTO, cautious use of oral nitrates may be considered.
9.4 Atrial tachyarrhythmia

Atrial fibrillation is the most common arrhythmia in patients with HCM. Predisposing factors include increased left atrial pressure and size, caused by diastolic dysfunction, LVOTO and mitral regurgitation. In a recent systematic review, the prevalence and annual incidence of AF were 22.5% and 3.1%, respectively; the prevalence and annual incidence of thromboembolism (stroke and peripheral embolism) in patients with AF were 27.1% and 3.8%. Clinical features most closely associated with paroxysmal or permanent AF include age and left atrial enlargement. Other possible predictors include LVOTO, P-wave duration >140 ms on signal-averaged ECG, paroxysmal SVT, ST-T changes on baseline electrocardiography, premature ventricular contractions, LGE on CMR, and abnormal coronary flow reserve. Reported predictors of thromboembolic events include paroxysmal or chronic AF, severe symptoms (NYHA functional Classes III and IV), older age, increased left atrial volume index, male sex and a history of heart failure admissions.

As left atrial size is a consistent predictor for AF and stroke in patients with HCM, patients in sinus rhythm with LA diameter ≥45 mm should undergo 6–12 monthly 48-hour ambulatory ECG monitoring to detect AF.

---

**Recommendations for chest pain on exertion in patients without left ventricular outflow tract obstruction**

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Class*</th>
<th>Level*</th>
<th>Ref.*</th>
</tr>
</thead>
<tbody>
<tr>
<td>ß-Blockers and calcium antagonists should be considered, to improve symptoms in patients with angina-like chest pain and no evidence for LVOTO or obstructive coronary artery disease.</td>
<td>I la</td>
<td>C</td>
<td>347–351</td>
</tr>
<tr>
<td>Oral nitrates may be considered, to improve symptoms in patients with angina-like chest pain and no evidence for LVOTO or obstructive coronary artery disease.</td>
<td>IIb</td>
<td>C</td>
<td></td>
</tr>
</tbody>
</table>

LVOTO = left ventricular outflow tract obstruction.
*Class of recommendation.
*Level of evidence.
*Reference(s) supporting recommendations.

---

**Figure 6** Algorithm for the treatment of heart failure in hypertrophic cardiomyopathy. ACEi = angiotensin converting enzyme inhibitor; AF = atrial fibrillation; LVEF = left ventricular ejection fraction; LVOTO = left ventricular outflow tract obstruction; MRA = mineralocorticoid receptor antagonist; NYHA = New York Heart Association.
There are fewer data on the prevalence and characteristics of atrial flutter and other atrial arrhythmias but, in general, atrial flutter should be managed conventionally and the risk of thromboembolism considered the same as for AF.

9.4.1 Acute treatment

New-onset AF is frequently associated with heart failure symptoms and so should be treated promptly in accordance with ESC guidelines. Immediate direct current (DC) cardioversion is recommended in haemodynamically unstable patients. If patients have severe symptoms of angina or heart failure, intravenous β-blockers or amiodarone are recommended.

In haemodynamically stable patients, oral β-blockers or non-dihydropyridine calcium channel antagonists are recommended to slow the ventricular response to AF. If pre-excitation is present, non-dihydropyridine calcium channel antagonists and adenosine are contraindicated. Digoxin should be avoided in patients with LVOTO and normal EF. Similarly, Class IC anti-arrhythmics, such as flecainide and propafenone, should be avoided as they may prolong QRS duration and the QT interval, and increase the ventricular rate due to conversion to atrial flutter and 1:1 ventricular conduction.

When rate control is achieved, elective DC cardioversion should be considered after a minimum of 3 weeks effective [international normalized ratio (INR) between 2.0 and 3.0] anticoagulation with a vitamin K antagonist (VKA). If earlier DC cardioversion is contemplated, a TOE-based strategy should be followed in accordance with ESC guidelines.

9.4.2 Thromboembolism prophylaxis

The ESC Guidelines on stroke prophylaxis in patients with AF recommend a risk factor-based approach in which the risk for patients with non-valvular AF is calculated from a scoring system known as ‘congestive heart failure, hypertension, age ≥75 (doubled), diabetes, stroke (doubled), vascular disease, age 65–74, and female sex’ (CHA2DS2-VASc). As patients with HCM tend to be younger than other high risk groups and have not been included in clinical trials of thromboprophylaxis, use of the CHA2DS2-VASc score to calculate stroke risk is not recommended.

Given the high incidence of stroke in patients with HCM and paroxysmal, persistent or permanent AF, it is recommended that all patients with AF should receive treatment with VKA. In general, lifelong therapy with oral anticoagulants is recommended, even when sinus rhythm is restored.

Two observational studies have reported lower rates of stroke in patients treated with warfarin than in those on antiplatelets or no therapy. Thus, therapy with a combination of aspirin 75–100 mg and clopidogrel 75 mg daily should be considered only in patients who are unable or unwilling to take oral anticoagulants (OAC). Assessment of the risk of bleeding is recommended when prescribing antithrombotic therapy (whether with VKA, or aspirin in combination with clopidogrel). Even though the ‘hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile INR, elderly (>65 years), drugs/alcohol concomitantly’ (HAS-BLED) score was not evaluated in patients with HCM, it would seem to be a reasonable tool to assess the risk of bleeding. A HAS-BLED score of ≥3 indicates high bleeding risk and caution should be exercised, with regular clinical reviews.

There are no randomized, controlled trials examining the effect of anti-arrhythmic drugs or radiofrequency ablation on long-term prevention of AF in patients with HCM. One observational study demonstrated that amiodarone therapy was associated with maintenance of sinus rhythm and fewer alterations in drug therapy, embolic episodes and attempted DC cardioversion.

Others have shown that, in patients variously treated with amiodarone, β-blockers or calcium channel blockers, there was no significant difference in the duration of sinus rhythm and survival after the first episode of AF. The short-term, double-blind, cross-over study (n = 30) demonstrated suppression of supraventricular arrhythmia with sotalol. Disopyramide is used to treat LVOTO, but its effect on AF suppression in HCM is unknown. There are also no systematic data on the use of renalome in patients with HCM but, in view of recent studies showing an increase in cardiovascular events including cardiovascular mortality, it is not recommended in HCM.

There are few data on catheter ablation for AF in patients with HCM, but the technique should be considered in patients without severe left atrial enlargement, who have drug refractory
67% of patients; failure to suppress AF is associated with left atrial size and older age. 357, 358

Medium-term maintenance of sinus rhythm is achieved in up to 35% of patients who develop persistent, permanent or paroxysmal AF, to prevent thromboembolism.

Antithrombotic therapy is recommended for patients with atrial flutter, as for those with AF.

Assessment of the risk of bleeding with the HAS-BLED score should be considered when prescribing antithrombotic therapy (whether with VKA or antiplatelet therapy).

Restoration of sinus rhythm, by DC or pharmacological cardioversion with intravenous amiodarone, should be considered in patients presenting with recent-onset AF.

Amiodarone should be considered for achieving rhythm control and to maintain sinus rhythm after DC cardioversion.

8-Blockers, verapamil and diltiazem are recommended for controlling ventricular rate in patients with permanent or persistent AF.

Catheter ablation for atrial fibrillation should be considered in patients without severe left atrial enlargement, who have drug refractory symptoms or are unable to take anti-arrhythmic drugs.

Ablation of the AV node to control heart rate may be considered when the ventricular rate cannot be controlled with drugs and when AF cannot be prevented by anti-arrhythmic therapy or is associated with intolerable side-effects.

Following AV node ablation in patients with an LVEF ≤50%, implantation of a dual-chamber (DDD) pacemaker with mode-switch function is recommended for patients with paroxysmal AF and a single-chamber (VVIR) pacemaker for those in persistent or permanent AF.

In patients with any type of AF and LVEF <50%, implantation of a CRT pacemaker may be considered after AV node ablation.

9.5 Sudden cardiac death

Most contemporary series of adult patients with HCM report an annual incidence for cardiovascular death of 1–2%, with SCD, heart failure and thromboembolism being the main causes of death. 364 The most commonly recorded fatal arrhythmic event is spontaneous ventricular fibrillation (VF), but asystole, AV block and pulseless electrical activity are described. 365, 366

9.5.1 Clinical risk assessment

Estimation of SCD risk is an integral part of clinical management. A large body of evidence suggests that, in adolescents and adults, the risk assessment should comprise of clinical and family history, 48-hour ambulatory ECG, TTE (or CMR in the case of poor echo windows) and a symptom-limited exercise test. Clinical features that are associated with an increased SCD risk and that
have been used in previous guidelines to estimate risk are shown in Table 7.

9.5.2 Models for estimating sudden cardiac death risk

Trials in other cardiovascular diseases have shown that implantation of an ICD for primary and secondary prophylaxis can reduce mortality; however, the threshold of risk that justifies device implantation of an ICD for primary and secondary prophylaxis can reduce mortality. Trials in other cardiovascular diseases have shown that implantation of an ICD for primary and secondary prophylaxis can reduce mortality. However, the threshold of risk that justifies device implantation of an ICD for primary and secondary prophylaxis can reduce mortality. These include age, NSVT, maximal LV wall thickness, family history of sudden cardiac death at a young age, syncope, left atrial diameter, left ventricular outflow tract obstruction, and exercise blood pressure response.

### Table 7: Major clinical features associated with an increased risk of sudden cardiac death in adults

<table>
<thead>
<tr>
<th>Risk Factor</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>• The effect of age on SCD has been examined in a number of studies and two have shown a significant association, with an increased risk of SCD in younger patients. However, some risk factors appear to be more important in younger patients, most notably, NSVT, severe LVH, and unexplained syncope.</td>
</tr>
<tr>
<td>Non-sustained ventricular tachycardia</td>
<td>• NSVT (defined as 3 consecutive ventricular beats at ≥120 BPM lasting &lt;30 seconds) occurs in 20–30% of patients during ambulatory ECG monitoring and is an independent predictor of SCD. There is no evidence that the frequency, duration or rate of NSVT influences the risk of SCD.</td>
</tr>
<tr>
<td>Maximum left ventricular wall thickness</td>
<td>• The severity and extent of LVH measured by TTE are associated with the risk of SCD. Several studies have shown the greatest risk of SCD in patients with a maximum wall thickness of ≥30 mm but there are few data in patients with extreme hypertension (≥35 mmHg).</td>
</tr>
<tr>
<td>Family history of sudden cardiac death at a young age</td>
<td>• While definitions vary, a family history of SCD is usually considered clinically significant when one or more first-degree relatives have died suddenly aged &lt;40 years with or without a diagnosis of HCM, or when SCD has occurred in a first-degree relative at any age with an established diagnosis of HCM.</td>
</tr>
<tr>
<td>Syncope</td>
<td>• Syncope is common in patients with HCM but is challenging to assess as it has multiple causes. Non-neurocardiogenic syncope for which there is no explanation after investigation is associated with increased risk of SCD. Episodes within 6 months of evaluation may be more predictive of SCD.</td>
</tr>
<tr>
<td>Left atrial diameter</td>
<td>• Two studies have reported a positive association between LA size and SCD. There are no data on the association between SCD and LA area and volume. Measurement of LA size is also important in assessing the risk of AF (see section 9.4).</td>
</tr>
<tr>
<td>Left ventricular outflow tract obstruction</td>
<td>• A number of studies have reported a significant association with LVOTO and SCD. Several unanswered questions remain, including the prognostic importance of provokable LVOTO and the impact of treatment (medical or invasive) on SCD.</td>
</tr>
<tr>
<td>Exercise blood pressure response</td>
<td>• Approximately one third of adult patients with HCM have an abnormal systolic blood pressure response to exercise characterised by progressive hypotension or a failure to augment the systolic blood pressure that is caused by an inappropriate drop in systemic vascular resistance and a low cardiac output reserve. Various definitions for abnormal blood pressure response in patients with HCM have been reported; for the purposes of this guideline an abnormal blood pressure response is defined as a failure to increase systolic pressure by at least 20 mm Hg from rest to peak exercise or a fall of &gt;20 mm Hg from peak pressure. Abnormal exercise blood pressure response is associated with a higher risk of SCD in patients aged ≥40 years, but its prognostic significance in patients ≤40 years of age is unknown.</td>
</tr>
</tbody>
</table>

HCM = hypertrophic cardiomyopathy; LA = left atrium; LVH = left ventricular hypertrophy; LVOTO = left ventricular outflow tract obstruction; NSVT = non-sustained ventricular tachycardia; SCD = sudden cardiac death; TTE = transthoracic echocardiography.

SCD, unexplained syncope, and abnormal blood pressure response to exercise were used to estimate risk and to guide ICD therapy. This approach has a number of limitations: specifically, it estimates relative—and not absolute—risk; it does not account for the different effect size of individual risk factors; and some risk factors such as LV wall thickness are treated as binary variables when they are associated with a continuous increase in risk. Consequently, current risk algorithms discriminate modestly between high- and low-risk patients.

Other clinical features, such as myocardial fibrosis (determined by contrast enhanced CMR), LV apical aneurysms and the inheritance of multiple sarcomere protein gene mutations, have been suggested as arbiters that can be used to guide ICD therapy in individuals who are at an intermediate risk, but there are few data to support this approach.

Recently, a multicentre, retrospective, longitudinal cohort study of 3675 patients—known as HCM Risk-SCD—developed and validated a new SCD risk prediction model. HCM Risk-SCD uses predictor variables that have been associated with an increased risk of sudden death in at least one published multivariable analysis (Web Table 5). This excludes abnormal blood pressure response as a risk factor. The model provides individualized 5-year risk estimates.
and, in a head to head comparison with a model using four major risk factors, the performance of the prediction model improved substantially (C-index from 0.54 to 0.7) and compared favourably with other similar prediction algorithms such as CHA2DS2-VASc. 373

The HCM Risk-SCD formula is as follows:

\[
\text{Probability}_{\text{SCD at 5 years}} = 1 - 0.998^{\exp(\text{Prognostic index})}
\]

where Prognostic index = \(0.15939858 \times \text{maximal wall thickness (mm)} + 0.0259082 \times \text{left atrial diameter (mm)} + 0.00446131 \times \text{maximal (rest/Valsalva) left ventricular outflow tract gradient (mm Hg)} + 0.4583802 \times \text{family history SCD} + 0.82639175 \times \text{NSVT} + 0.71650361 \times \text{unexplained syncope} - 0.01799934 \times \text{age at clinical evaluation (years)}\].

N.B. In HCM Risk-SCD there was a non-linear relationship between the risk of SCD and maximum left ventricular wall thickness. 73 This is accounted for in the risk prediction model by the inclusion of a quadratic term for maximum left ventricular wall thickness.

9.5.3 Prevention of sudden cardiac death

9.5.3.1 Exercise restriction

Although documented exercise-induced, sustained, ventricular arrhythmias are rare—and most ICD therapies for ventricular arrhythmias occur in the absence of tachycardia or physical exertion—patients with HCM should be advised against participation in competitive sports and discouraged from intense physical activity, especially when they have risk factors for SCD and/or LVOTO.

9.5.3.2 Anti-arrhythmic drugs

There are no randomized, controlled data to support the use of anti-arrhythmics for the prevention of SCD in HCM. Amiodarone was associated with a lower incidence of SCD in one small observational study of patients with NSVT on Holter monitoring and in others, increased the threshold for VF, but observational data suggest that amiodarone often fails to prevent SCD. 389, 390 Disopyramide does not appear to have a significant impact on the risk of SCD. 267

9.5.3.3 Implantable cardioverter defibrillators

9.5.3.3.1 Secondary prophylaxis. Patients with HCM who survive VF or sustained ventricular tachycardia are at very high risk of subsequent lethal cardiac arrhythmias and should receive an ICD. 327, 367–393 In clinical practice, this population is very small and ICD therapy rarely poses a clinical dilemma. 327 There are few data on exercise-induced ventricular arrhythmias but data from one study suggests that it is associated with a high risk of sudden cardiac death. 346

9.5.3.3.2 Primary prophylaxis. Identification of individuals without a history of VF, who are at high risk of SCD, remains a challenge and only a small subgroup of individuals currently treated with an ICD receives potentially lifesaving shocks. 394 At the same time, a large number of ICD recipients experience inappropriate shocks and implant complications. 327

In these Guidelines, it is recommended that patients undergo a standardized clinical evaluation (see Web Table 5 and Figure 7) that records a pre-defined set of prognostic variables, which are then used to estimate the 5-year risk of SCD using the HCM Risk-SCD model [a Web-based calculator is provided with these Guidelines (www.escardio.org/guidelines-surveys/esc-guidelines/Pages/hypertrophic-cardiomyopathy.aspx)].

Recommended on prevention of sudden cardiac death

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Class</th>
<th>Level</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Avoidance of competitive sports is recommended in patients with HCM</td>
<td>I</td>
<td>C</td>
<td>395</td>
</tr>
<tr>
<td>ICD implantation is recommended in patients who have survived a cardiac arrest due to VT or VF, or who have spontaneous sustained VT causing syncope or haemodynamic compromise, and have a life expectancy of &gt;1 year</td>
<td>I</td>
<td>B</td>
<td>327, 367, 391–393</td>
</tr>
<tr>
<td>HCM Risk-SCD is recommended as a method of estimating risk of sudden death at 5 years in patients aged &gt;816 years without a history of resuscitated VT/VF or spontaneous sustained VT causing syncope or haemodynamic compromise</td>
<td>I</td>
<td>B</td>
<td>73</td>
</tr>
<tr>
<td>It is recommended that the 5-year risk of SCD be assessed at first evaluation and re-evaluated at 1–2 year intervals or whenever there is a change in clinical status</td>
<td>I</td>
<td>B</td>
<td>73</td>
</tr>
<tr>
<td>ICD implantation should be considered in patients with an estimated 5-year risk of sudden death of &gt;4% and a life expectancy of &gt;1 year, following detailed clinical assessment that takes into account the lifelong risk of complications and the impact of an ICD on lifestyle, socio-economic status and psychological health</td>
<td>IIa</td>
<td>B</td>
<td>73, 327, 393, 396</td>
</tr>
<tr>
<td>ICD implantation may be considered in individual patients with an estimated 5-year risk of SCD between 24% and &lt;6% and a life expectancy of &gt;1 year, following detailed clinical assessment that takes into account the lifelong risk of complications and the impact of an ICD on lifestyle, socio-economic status and psychological health</td>
<td>IIb</td>
<td>B</td>
<td>73, 327, 393, 396</td>
</tr>
<tr>
<td>ICD implantation may be considered in individual patients with an estimated 5-year risk of SCD of &lt;4% only when they have clinical features that are of proven prognostic importance, and when an assessment of the lifelong risk of complications and the impact of an ICD on lifestyle, socio-economic status and psychological health suggests a net benefit from ICD therapy</td>
<td>IIb</td>
<td>B</td>
<td>73, 327, 393, 396</td>
</tr>
<tr>
<td>ICD implantation is not recommended in patients with an estimated 5-year risk of SCD of &lt;4% and no other clinical features that are of proven prognostic importance</td>
<td>III</td>
<td>B</td>
<td>73, 327, 393, 396</td>
</tr>
</tbody>
</table>

ICD = implantable cardioverter defibrillator; VF = ventricular fibrillation; VT = ventricular tachycardia.

C = Class of recommendation.

B = Level of evidence.

*Reference(s) supporting recommendations.

ESCC Guidelines define competitive sport as amateur or professional engagement in exercise training on a regular basis and participation in official competitions (see relevant ESC Guidelines for more detail). 295

The published HCM Risk-SCD dataset has been used to construct three categories of risk (high, intermediate and low) that were determined by consensus (Figure 7). The recommendations for
ICD therapy in each risk category take into account not only the absolute statistical risk, but also the age and general health of the patient, socio-economic factors and the psychological impact of therapy. The recommendations are meant to be sufficiently flexible to account for scenarios that are not encompassed by the HCM Risk-SCD model.

**HCM Risk-SCD should not be used in patients <16 years of age, elite athletes or in individuals with metabolic/infiltrative diseases (e.g. Anderson-Fabry disease) and syndromes (e.g. Noonan syndrome). The model does not use exercise-induced LV outflow tract gradients and has not been validated before and after myectomy or alcohol septal ablation.**

As the relationship between maximum LV wall thickness and risk is non-linear, the calculated risk for SCD falls in patients with severe LVH ($\geq 35$ mm). This may reflect small numbers in this category but, as shown in the source paper, the rate of sudden deaths was

---

**Figure 7** Flow chart for ICD implantation.
very low in this group. This phenomenon has been seen in at least one previous study.99

Pending further studies, HCM-RISK should be used cautiously in patients with a maximum left ventricular wall thickness ≥ 35 mm.

Implantable cardioverter defibrillators are not recommended when the estimated 5-year risk of SCD is < 4% and there are no other clinical features that are of potential prognostic importance (for example multiple young sudden deaths in a family or an abnormal exercise blood pressure response). When such features are present, decisions on ICDs must be made on an individual basis and must balance the likely benefit against the lifelong risk of complications and the impact of an ICD on lifestyle, socio-economic status and psychological health.

9.5.3.3.3 Practical aspects of ICD therapy

Prior to ICD implantation, patients should be counselled on the risk of inappropriate shocks, implant complications, and the social and occupational implications (including driving restrictions) of an ICD. Studies examining the role of defibrillation testing at the time of implantation are continuing, but high defibrillation thresholds are reported when the estimated 5-year risk of SCD is < 4%. Until data specific to HCM are available, defibrillation testing may be considered at the physician’s discretion. For patients who have a high defibrillation threshold or who fail to cardiovert on defibrillation testing, options include sub-pectoral implantation and standard manoeuvres such as reversal of shocking vector polarity, changing the shock tilt, including/excluding a superior vena cava coil followed by re-testing and, if necessary, implantation of a subcutaneous array.

The VF zone of the device should be programmed at ≥ 220/min to minimize shocks from rapidly conducted AF. An SVT discrimination zone, tailored to individual patient characteristics, may also be considered. Observational data show that anti-tachycardia pacing is effective in terminating ventricular arrhythmias in HCM but does not reduce the incidence of appropriate shocks.387,401 As atrial leads do not reduce the incidence of inappropriate shocks,327,393,396 most patients require only a single ventricular lead. Exceptions include patients with LVOTO, in whom an atrial lead provides the option for a short AV delay pacing, and patients in sinus rhythm with impaired LV systolic function, in whom CRT might be preferable (see section 9.3.1.2). In the light of results from the Multicenter Automatic Defibrillator Implantation Trial—Reduce Inappropriate Therapy (MADIT-RIT), shock-only programming can be considered in primary prevention, although this trial was conducted in patients with low EF.402

ß-Blockers and/or amiodarone are recommended in patients with an ICD, who continue to have symptomatic ventricular arrhythmias or recurrent shocks despite optimal treatment and device re-programming.219 Electrophysiological study is recommended in patients with ICDs and inappropriate shocks due to regular supraventricular tachycardias, to identify and treat any ablatable arrhythmia substrate. A subcutaneous ICD lead system (S-ICD™) may be considered in HCM patients who do not have an indication for pacing.403

T-wave oversensing. Each patient should have more than one ECG vector that passes screening, to allow alternative programming if oversensing does occur.405,407 Data from a multicentre registry that included 58 HCM patients provided preliminary efficacy and safety data.407

<table>
<thead>
<tr>
<th>Recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prior to ICD implantation, patients should be counselled on the risk of inappropriate shocks, implant complications and the social, occupational, and driving implications of the device.</td>
</tr>
<tr>
<td>Class: I</td>
</tr>
<tr>
<td>Level: C</td>
</tr>
<tr>
<td>Ref: 219,327</td>
</tr>
<tr>
<td>ß-Blockers and/or amiodarone are recommended in patients with an ICD, who have symptomatic ventricular arrhythmias or recurrent shocks despite optimal treatment and device re-programming.</td>
</tr>
<tr>
<td>Class: I</td>
</tr>
<tr>
<td>Level: C</td>
</tr>
<tr>
<td>Ref: 219,403</td>
</tr>
<tr>
<td>Electrophysiological study is recommended in patients with ICDs and inappropriate shocks due to regular supraventricular tachycardias, to identify and treat any ablatable arrhythmia substrate.</td>
</tr>
<tr>
<td>Class: I</td>
</tr>
<tr>
<td>Level: C</td>
</tr>
<tr>
<td>Ref: 403</td>
</tr>
</tbody>
</table>

HCM = hypertrophic cardiomyopathy; ICD = implantable cardioverter defibrillator; S-ICD™ = subcutaneous ICD lead system

9.5.4 Risk of sudden death in children

Implantation of an ICD (epicardial if necessary) is indicated after a life-threatening ventricular arrhythmia in children. In very young children (< 8 years old), clinical risk stratification to determine the need for primary prophylaxis with an ICD is hampered by a lack of data. The risk of death or heart transplantation is greatest in infants or in patients with inherited metabolic disorders and malformation syndromes.108 There is general agreement that, as in adults, severe LVH, unexplained syncope, NSVT and a family history of sudden death represent major risk factors for sudden cardiac death.109 The definition of severe hypertrophy in infants, children and pre-adolescents has been assessed using different approaches and measurements.410,411 The consensus view for these Guidelines is that a maximum left ventricular wall thickness ≥ 30 mm or a Z-score ≥ 6 is considered to be a major risk factor in children.110

Implantation of an ICD should be considered in children who have two or more major risk factors. Single-chamber defibrillators suffice in the majority of cases and reduce the likelihood of complications.412 In individual patients with a single risk factor, ICD implantation may be considered after careful consideration of the risks and benefits to the child and family.
9.7 Ventricular tachycardia

Non-sustained ventricular tachycardia (defined as three or more ventricular extrasystoles at a rate of \( \geq 120 \) BPM, lasting \(<30\) seconds) is a common finding on ambulatory ECG monitoring.\(^{59,70,417,418}\) Its prevalence increases with age and correlates with LV wall thickness and the presence of late gadolinium enhancement on CMR.\(^{69,440}\)

Non-sustained ventricular tachycardia is a risk factor for SCD, but does not usually require anti-arrhythmic therapy. Its occurrence during or immediately following exercise is very rare, but may be associated with a high risk of SCD.\(^{246}\)

Documented sustained monomorphic VT (\( \geq 30\) seconds) is uncommon but may be more frequent in patients with apical LV aneurysms.\(^{256,419}\) Exclusion of coronary artery disease should be considered in patients with prolonged or symptomatic episodes and risk factors for coronary atherosclerosis. There is no evidence that haemodynamically tolerated, sustained VT carries a worse prognosis than NSVT but it should be considered as a risk factor for SCD. Patients with poorly tolerated VT should be considered for ICD therapy and treatment with \( \beta \)-blockers or amiodarone, to suppress further episodes. In patients with evidence for a focal origin, EPS and ablation may be considered.\(^{420-422}\)

10. Recommendations for routine follow-up

In general, patients with HCM require lifelong follow-up to detect changes in symptoms, risk of adverse events, LVOTO, LV function and cardiac rhythm.

There are very few longitudinal data on the rates of change in symptoms or cardiac function, but cross-sectional studies show that the prevalence of LV systolic dysfunction and atrial arrhythmia increases with advancing age.\(^{222,224,225,423}\) The frequency of monitoring is determined by the severity of disease, age and symptoms. A clinical examination, including 12-lead ECG and TTE, should be performed every 1–2 years, or sooner should patients complain of new heart failure symptoms. Ambulatory electrocardiography is recommended every year (or every 6 months in the presence of left atrial dilation \( \geq 45 \) mm) to detect asymptomatic atrial and ventricular arrhythmia, and is indicated whenever patients experience syncope or palpitations.

When available, cardiopulmonary exercise testing can provide objective evidence for worsening disease but need only be performed every 2–3 years unless there is a change in symptoms. There are few data on changes in myocardial fibrosis on CMR during follow-up but, when available, CMR evaluation may be considered every five years or every 2–3 years in patients with progressive disease.\(^{424}\)

A complete assessment, including ECG, TTE and ambulatory ECG monitoring should be performed within 1–3 months and at 6–12 months following invasive septal reduction therapies.
11. Reproduction and contraception

11.1 Introduction

Pregnancy is associated with many physiological changes, including a 40–50% increase in plasma volume and cardiac output, a reduction in systemic vascular resistance and a hypercoagulable state. Whilst most women with HCM have uncomplicated pregnancies, these physiological changes are associated with increased risk for mother and foetus, as the volume load can be poorly tolerated in the setting of LVOTO and diastolic dysfunction. Adequate and timely counselling on contraception, the risks associated with pregnancy, and the risk of disease transmission to the foetus is important in all women with HCM.427,428

11.2 Contraception and termination of pregnancy

When a girl with HCM reaches fertility, she should be counselled to use safe and effective contraception, since unplanned pregnancy carries an increased risk.429 Barrier methods (condoms, diaphragms, pelvic ring) are safe but not as effective as oral contraceptives, even when combined with spermicides (failure rate at 1 year 15–30%). Low dose oral contraceptives with 20 μg or 30 μg ethinyl-oestradiol are effective (though less so in adolescents) and can be safely used in most women with HCM, except for those with increased thromboembolic risk (e.g. women with heart failure or AF), unless they are using adequate oral anticoagulation therapy. Oral contraceptives are inadvisable in any women who smoke and are older than 35 years or who have a history of venous thromboembolism. Emergency contraception is safe for women with HCM.427,429 Progesterone-only contraceptives are a safe alternative but the effectiveness of the progesterone-only pill (desogestrel) depends on compliance (daily intake with <12 hours of variation). Other progesterone-only contraceptives can be used, including 3-monthly injections with medroxyprogesterone acetate or dermal progesterone implants, but should be used cautiously in women with diastolic or systolic heart failure because of the risk of fluid retention. The levonorgestrel-releasing intra-uterine device (IUD) is a safe and effective alternative. Progesterone-only methods are not always tolerated because of irregular blood loss. A copper IUD may be used but is less effective and is associated with an increase in monthly blood loss. Antibiotic prophylaxis at the time of IUD insertion is not necessary, but vasovagal reactions can occur during implantation and, in women with severe LVOTO, it should therefore be implanted after cardiology consultation and in a hospital setting.

Sterilization can be safely accomplished by tubal ligation, although the risks of anaesthesia and abdominal inflation should be considered. Hysteroscopic sterilization with an Essure™ device (Bayer) is an alternative but can also be associated with vasovagal reactions.427,429 Termination of pregnancy should be performed in-hospital after consultation with a cardiologist. Dilation and evacuation are usually safe; as prostaglandin E1 or E2 can lower systemic vascular resistance and increase heart rate, haemodynamic monitoring is indicated. Prostaglandin F increases pulmonary artery pressure and should be avoided.427

11.3 Infertility treatment

In vitro fertilization can be associated with fluid retention and with arterial and venous thromboembolism. It is probably safe in low-risk HCM patients, but should be avoided in patients with heart failure or AF and in women with severe hypertrophy and restrictive LV filling pattern.427 When pre-implantation genetic diagnosis (see section 6) is an issue, the risk of in vitro fertilization should be taken into account.

11.4 Pre-conception counselling

Most women with HCM tolerate pregnancy well. The hypertrophied small left ventricle can, in most cases, accommodate the physiological increase in blood volume without undue rise in filling pressures. The few reported cases of maternal death have occurred mostly in women who were known to be at very high risk.430–432 Deterioration during pregnancy most often occurs in women who are symptomatic before pregnancy.431–433,434 The prevalence of heart failure during pregnancy differs between studies but it is probably more likely in women who had impaired LV function before pregnancy.431–433,435,436 Left ventricular outflow tract gradients tend to increase slightly during pregnancy and high pre-pregnancy LVOT gradients have been reported to be associated with more pregnancy complications.430–432,434,436 Women with arrhythmias
pre-pregnancy are more likely to experience recurrence in pregnancy, but pregnancy per se does not seem to substantially increase the risk of arrhythmias. Ideally, risk assessment should be performed before conception, using the modified World Health Organization (WHO) classification. Most HCM patients are WHO Class II or III (Table 8). Justification for advising against pregnancy (WHO Class IV) is present in a small minority with significant LV dysfunction or severe symptomatic LVOTO. Pregnancy may be possible after relief of LVOTO.

Echocardiography should be performed to evaluate ventricular function, mitral regurgitation and LVOTO. Exercise testing (preferably pre-pregnancy or, in asymptomatic pregnant women, to 80% of predicted maximal heart rate) is an important tool to assess functional capacity, heart rate response and arrhythmias. A plan for use of medication and follow-up during pregnancy should be made and discussed with the patient and her partner before conception. Genetic counselling is recommended in all women with HCM (see section 6).

Table 8: Modified WHO classification of maternal cardiovascular risk: principles and application

<table>
<thead>
<tr>
<th>Risk class</th>
<th>Risk of pregnancy</th>
<th>Application to HCM</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>No detectable increased risk of maternal mortality and no/minimal risk of morbidity</td>
<td>-</td>
</tr>
<tr>
<td>II</td>
<td>Small increased risk of maternal mortality or moderate increase in morbidity</td>
<td>Most women with HCM; mild to moderate LVOTO; asymptomatic with or without medication, well-controlled arrhythmia, normal systolic LV function or mild LV dysfunction</td>
</tr>
<tr>
<td>III</td>
<td>Significantly increased risk of maternal mortality or severe morbidity</td>
<td>Severe LVOTO, symptoms or arrhythmias despite optimal medication, moderate systolic LV dysfunction</td>
</tr>
<tr>
<td>IV</td>
<td>Extremely high risk of maternal mortality or severe morbidity; pregnancy contraindicated</td>
<td>Severe systolic LV dysfunction, severe symptomatic LVOTO</td>
</tr>
</tbody>
</table>

HCM = hypertrophic cardiomyopathy; LV = left ventricle; LVOTO = left ventricular outflow tract obstruction; WHO = World Health Organization.
Because of increased risk of pulmonary oedema due to fluid shifts post-delivery, clinical observation should be continued for 24–48 hours.\textsuperscript{427} There is no need to deactivate an ICD during vaginal post-delivery.

**Recommendations on reproductive issues in women with hypertrophic cardiomyopathy**

<table>
<thead>
<tr>
<th>Recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pre-pregnancy risk assessment and counselling is indicated in all women.</td>
</tr>
<tr>
<td>Counselling on safe and effective contraception is indicated in all women of fertile age.</td>
</tr>
<tr>
<td>Counselling on the risk of disease transmission is recommended for all men and women before conception.</td>
</tr>
<tr>
<td>(\beta)-Blockers (preferably metoprolol) should be continued in women who used them before pregnancy.</td>
</tr>
<tr>
<td>(\beta)-Blockers (preferably metoprolol) should be started in women who develop symptoms during pregnancy.</td>
</tr>
<tr>
<td>Whenever (\beta)-blockers are prescribed, monitoring of foetal growth and of the condition of the neonate is recommended.</td>
</tr>
<tr>
<td>Scheduled (induced) vaginal delivery is recommended as first choice in most patients</td>
</tr>
<tr>
<td>Therapeutic anticoagulation with LMWH or vitamin K antagonists depending on the stage of pregnancy\textsuperscript{4} is recommended for atrial fibrillation.</td>
</tr>
<tr>
<td>Cardioversion should be considered for persistent atrial fibrillation.</td>
</tr>
</tbody>
</table>

LMWH = low molecular weight heparin.
\textsuperscript{4}Class of recommendation.
\textsuperscript{4}Level of evidence.
\textsuperscript{4}Reference(s) supporting recommendations.
\textsuperscript{4}See text for details.

**12.2 Hypertension**

In clinical practice, it can be a challenge to make a differential diagnosis between hypertensive heart disease on the one hand and HCM associated with systemic hypertension on the other. Regression of LVH with treatment of hypertension argues against the diagnosis of HCM, but the reverse is not necessarily true.\textsuperscript{461–466} Clinical features that suggest a diagnosis of HCM in a patient with hypertension are summarized in Table 9.

**12.2.1 Imaging**

Increased LV mass, determined by echocardiography, is present in >30% of hypertensive patients.\textsuperscript{467} The degree of hypertrophy is influenced by ethnicity, neurohumoral factors, and genetic variants.\textsuperscript{468–476} In general, maximal LV wall thickness is greater in patients with unequivocal HCM, but there is overlap between the two conditions.\textsuperscript{471–477} The majority of patients with hypertensive LVH have a maximal interventricular septal thickness <15 mm,\textsuperscript{474–477} but in black patients (particularly in the presence of chronic kidney disease) maximal interventricular septal thickness is not uncommonly between 15 and 20 mm.\textsuperscript{478} Late gadolinium enhancement is reported in the mid-myocardium and epicardium in both hypertension and HCM,\textsuperscript{136} but tends to be located in the segment with the greatest wall thickness and at the RV insertion points in HCM.\textsuperscript{136} Similarly, while diastolic abnormalities and LA dilation are seen in HCM and hypertension, severe diastolic dysfunction is more typical of HCM. Doppler myocardial imaging and strain imaging may help to distinguish the two entities.\textsuperscript{479–480} Resting or exercise-induced LVOTO can be observed in hypertension and does not constitute a diagnostic criterion.\textsuperscript{481,482}

**12.2.2 Electrocardiogram**

On the 12-lead ECG, LVH by voltage criteria is seen in 10–20% of hypertensive patients with LVH, but—at least in Caucasians—marked repolarisation abnormalities, conduction abnormalities and Q-waves are unusual.\textsuperscript{483–484} Atrial fibrillation is common in both conditions, affecting approximately one-third of patients. Premature ventricular complexes and NSVT are reported in up to 30% of patients with hypertension complicated by LVH.\textsuperscript{485–487}

**12.3 Isolated basal septal hypertrophy (sigmoid septum) in elderly people**

Some elderly people have mild basal septal hypertrophy (sometimes referred to as a sigmoid septum or septal bulge) associated with increased angulation between the aorta and LV cavity. Many have a history of hypertension and some have calcification of the mitral valve annulus. The limited data suggest that individuals with this
pattern of ventricular remodelling are less likely to have familial disease or a mutation in a cardiac sarcomeric protein gene. Importantly, due to provokable LVOTO, some patients with basal septal hypertrophy experience symptoms on exertion and should be assessed using physiological provocation and stress echocardiography in the same way as patients with unequivocal HCM. Advice on family screening in this group is challenging, but should be guided by the implications for family members and the presence of suspicious symptoms in relatives.

12.4 Diagnosis and management of valve disease in patients with hypertrophic cardiomyopathy

12.4.1 Aortic valve disease

In the absence of a family history of HCM or a known history of HCM before the development of significant aortic valve disease, the differential diagnosis between, on the one hand, valvular aortic stenosis with severe LVH and, on the other, HCM associated with degenerative aortic valve disease can be challenging, particularly in the elderly with hypertension. In general, the pattern and severity of LV remodelling in aortic stenosis correlates modestly with the severity of valve narrowing. Between 20% and 30% have an asymmetric pattern of wall thickening, although the severity of hypertrophy is usually relatively mild (wall thickness ≤15 mm). Left ventricular wall thickness ≥15 mm has been reported in older hypertensive patients in small cohorts, who were examined using CMR. Systolic anterior motion and dynamic LVOTO is reported in patients with aortic stenosis and complicates accurate measurement of the valve gradient. The treatment of aortic stenosis should be in line with current ESC Guidelines. In patients with aortic stenosis and in whom dynamic obstruction is not demonstrated pre-operatively, septal myectomy is controversial and not recommended for routine use.

Up to one-third of patients with HCM have mild AR, probably caused by sub-aortic obstruction and high-velocity flow in the LV outflow tract. Moderate-to-severe AR is much less common and is usually caused by primary disease of the aortic valve leaflets or aortic root and infective endocarditis, when present in a patient with LVOTO, a non-SAM-related mechanism for obstruction, such as a sub-aortic membrane, should be excluded. Aortic regurgitation may also occur following septal myectomy, particularly in children and young adults. The severity of AR should be assessed in accordance with ESC guidelines by evaluating the anatomy of the valve, the size of the aortic root and of the ascending aorta, and other qualitative, semi-quantitative and quantitative parameters. The size of the LV cavity is an unreliable marker of the severity of AR in HCM.

12.4.2 Mitral valve disease

Mitral valve abnormalities secondary to LVOTO are discussed in section 9.1.3. The assessment of intrinsic mitral valve abnormalities can be challenging in the presence of LVOTO that, in itself, causes mitral regurgitation. The usual integrative approach to the assessment of mitral regurgitation, as recommended in the ESC-European Association for Cardio-Thoracic Surgery (EACTS) Guidelines on the management of valvular heart disease, has some limitations in HCM because the LV cavity is often small, even in the presence of severe mitral regurgitation, and conventional quantitative and semi-quantitative Doppler parameters are not validated in patients with LVOTO. In general, qualitative measures of valve anatomy—continuous wave and colour Doppler, combined with left atrial size and estimation of pulmonary artery pressure—are more helpful. In selected cases, TOE may be helpful in defining the mechanism and severity of mitral valve regurgitation.

12.4.3 Endocarditis prophylaxis

Infective endocarditis in HCM is virtually confined to patients with LV outflow obstruction, particularly in those with LA dilation. The incidence of endocarditis in patients with LVOTO was 3.8 per 1000 person-years and the probability of endocarditis 4.3% at 10 years of follow-up in a large cohort study. Endocardial lesions most commonly occur on the thickened anterior mitral leaflet or adjacent surface of the proximal ventricular septum. As in patients

---

**Table 9 Clinical features that assist in the differential diagnosis of hypertensive heart disease and hypertrophic cardiomyopathy**

<table>
<thead>
<tr>
<th>Clinical features favouring hypertension only</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal 12 lead ECG or isolated increased voltage without repolarisation abnormality</td>
</tr>
<tr>
<td>Regression of LVH over 6–12 months tight systolic blood pressure control (&lt;130 mm Hg)</td>
</tr>
</tbody>
</table>

**Clinical features favouring hypertrophic cardiomyopathy**

<table>
<thead>
<tr>
<th>Family history of HCM</th>
</tr>
</thead>
<tbody>
<tr>
<td>Right ventricular hypertrophy</td>
</tr>
<tr>
<td>Late gadolinium enhancement at the RV insertion points or localized to segments of maximum LV thickening on CMR</td>
</tr>
<tr>
<td>Maximum LV wall thickness ≥15 mm (Caucasian); ≥20 mm (black)</td>
</tr>
<tr>
<td>Severe diastolic dysfunction</td>
</tr>
<tr>
<td>Marked repolarisation abnormalities, conduction disease or Q-waves on 12 lead ECG</td>
</tr>
</tbody>
</table>

ECG = electrocardiogram; CMR = cardiac magnetic resonance imaging; HCM = hypertrophic cardiomyopathy; LV = left ventricle; LVH = left ventricular hypertrophy; RV = right ventricle.
with valve disease, good oral hygiene should be encouraged, but routine antibiotic prophylaxis is not recommended in patients with LV outflow tract gradients.\textsuperscript{503} Antibiotic prophylaxis should be considered for high-risk procedures in patients with prosthetic heart valves or prosthetic material used for valve repair, previous endocarditis or congenital heart disease, in accordance with the ESC/EACTS Guidelines on the management of valvular heart disease.\textsuperscript{993,503}

### 13. Living with cardiomyopathy: advice to patients

Most people with HCM lead normal and productive lives, but a small number experience significant symptoms and are at risk of disease-related complications. Irrespective of the severity of their disease, it is important that individuals receive support and accurate advice from family practitioners and other healthcare professionals, and that they are encouraged to understand and manage the disease themselves. Table 10 summarizes some of the key issues that should be discussed with patients, relatives and carers. When appropriate (for example, when considering pregnancy), patients should be referred to other specialist services.

#### 14. Appendix

ESC National Cardiac Societies actively involved in the review process of the 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy.

**Austria**: Austrian Society of Cardiology, Matthias Frick;  
**Azerbaijan**: Azerbaijan Society of Cardiology, Farid Aliyev;  
**Belarus**: Belorussian Scientific Society of Cardiologists, Svetlana

---

### Table 10 General lifestyle considerations for patients with hypertrophic cardiomyopathy

<table>
<thead>
<tr>
<th>Topic</th>
<th>General guidance</th>
</tr>
</thead>
</table>
| Exercise                     | • Patients with HCM should avoid competitive sports activities, but should maintain a healthy lifestyle  
• Advice on recreational activities should be tailored to symptoms and the risk of disease-related complications including sudden cardiac death                                                                                                                                                                                                 |
| Diet, alcohol and weight     | • Patients should be encouraged to maintain a healthy body mass index  
• Large meals can precipitate chest pain, particularly in patients with LVOTO. Smaller, more frequent meals may be helpful  
• Avoid dehydration and excess alcohol, particularly in patients with LVOTO  
• Constipation is a frequent side-effect of verapamil/desopiramid and should be managed with diet and if necessary aperients                                                                                                                                                                                                 |
| Smoking                      | • There are no data that show an interaction between tobacco smoking and HCM, but patients should be provided with general advice on the health risks associated with smoking and, when available, information on smoking cessation                                                                                                                                                                                                 |
| Sexual activity              | • Patients should be given the opportunity to discuss their concerns about sexual activity. Anxiety and depression following a diagnosis are frequent and some patients may express guilt or fear about their genetic diagnosis and the risk of transmission to offspring  
• Patients should be counselled on the potential effect of their medication on sexual performance  
• In general, patients should avoid PDE\textsubscript{5} inhibitors, particularly when they have LVOTO                                                                                                                                                                                                 |
| Medication                   | • Patients should be provided with information about their medication, including potential side-effects and interactions with prescribed medications, over-the-counter remedies and other complementary therapies  
• Where possible, peripheral vasodilators should be avoided in patients, particularly when they have LVOTO                                                                                                                                                                                                 |
| Vaccination                  | • In the absence of contraindications, symptomatic patients should be advised to have yearly influenza vaccination                                                                                                                                                                                                                              |
| Driving                      | • Most patients should be eligible for an ordinary driving licence and can continue driving unless they experience distracting or disabling symptoms  
• Advice on driving licences for heavy goods or passenger-carrying vehicles should be in line with local legislation  
• For further advice on driving with ICD see EHRA guidance\textsuperscript{504} and local rules                                                                                                                                                                                                 |
| Occupation                   | • Most people with HCM will be able to continue in their normal job. The implications of heavy manual jobs that involve strenuous activity should be discussed with the appropriate specialist  
• For some occupations such as pilots, and military and emergency services, there are strict guidelines on eligibility  
• The social and financial implications of a diagnosis of HCM should be included in the counselling of relatives before clinical or genetic screening                                                                                                                                                                                                 |
| Holidays and travel insurance| • Most asymptomatic or mildly symptomatic patients can fly safely. For further advice see Fitness to fly for passengers with cardiovascular diseases\textsuperscript{505}  
• Insurance companies may charge more for travel insurance. In some countries, patient support organizations can provide further advice about obtaining reasonable insurance                                                                                                                                                                                                 |
| Life insurance               | • The diagnosis of HCM will result in difficulty obtaining life insurance or mortgages. Advice on the rules that apply in different countries should be provided to patients at diagnosis                                                                                                                                                                                                 |
| Pregnancy and childbirth     | • See Reproduction and contraception (section 11)                                                                                                                                                                                                                                                                                                                                                   |
| Education/schooling          | • Teachers and other carers should be provided with advice and written information relevant to the care of children with HCM  
• In the absence of symptoms and risk factors, children should be allowed to perform low to moderate level aerobic physical activity, in accordance with advice from their cardiologist  
• Provision should be made for children with learning difficulties and other special needs                                                                                                                                                                                                 |

ICD = implantable cardioverter defibrillator; EHRA = European Heart Rhythm Association; HCM = hypertrophic cardiomyopathy; LVOTO = left ventricular outflow tract obstruction; PDE\textsubscript{5} = phosphodiesterase 5.
References


is selectively impaired in patients with hypertrophic cardiomyopathy and sarco- 

Matsushita A, Moravec CS, Seidman JG. Mutations in the genes for cardiac tropo- 
1058–1064.

27. Pasquale F, Syrris P, Kaski JP, Mogensen J, McKenna WJ, Elliott P. Long-term out- 
comes in hypertrophic cardiomyopathy caused by mutations in the cardiac tropo- 


hypertrophic cardiomyopathy caused by a Phe110Ile missense mutation in the cardiac tropinin T gene have variable cardiac morphologies and a favorable prog- 

Cecchi F. Prevalence and clinical profile of troponin T mutations among patients 


32. Lopes LR, Rahman MS, Elliott PM. A systematic review and meta-analysis of 
double mutations in patients with hypertrophic cardiomyopathy: implications for 

33. Ingles J, Doolan A, Chiu C, Seidman J, Seidman C, Semsarian C. Compound and 
dominant mutations in patients with hypertrophic cardiomyopathy: implications 

Isnard R, Dubourg O, Burban M, Guelfet JP, Millaire A, Desnos M, Schwartz K, 
Hainque B, Komajda M. Hypertrophic cardiomyopathy: distribution of disease 
genes, spectrum of mutations, and implications for a molecular diagnosis strategy. 

35. Girolami F, Ho CY, Sebillon P, Laforet P, Maisonobe T, Duboscq-Bidot L, 
Cocozza S. The relationship between trinucleotide (GAA) repeat length and clin- 

ence of Anderson-Fabry disease in patients with hypertrophic cardiomyopathy: 

Farrell M, Holton JL, Hanna MG, Hughes S, Elliott PM, MacRae CA, McKenna WJ, 
Adenosine monophosphate-activated protein kinase gene mutations mimics hypertroph-
Cardiol 2005;45:922–930.

Romero N, Dourain-Gaillard V, Freeburg T, Richard P, Eynard B, Komajda M, 
Danon’s disease: the cause of a hypertrophic cardiomyopathy: a systematic review. 

39. Limongelli G, Massarone D, D’Alessandro R, Elliott PM. Mitochondrial diseases and 
the heart: an overview of molecular basis, diagnosis, treatment and clinical course. 

Coccozza S. The relationship between trinucleotide (GAA) repeat length and clin- 

41. Lagerdrot SJ, Sutton MS, Cohen MS, Satou GM, Kaufman BD, Perlin SL, 
Rumney C, Meer T, Lynch DR. Idiobrachic in Friedreich ataxia cardiomyopathy 
results from a 6-month phase III study (IONIA). Am Heart J 2011;161: 
639–645.

42. Limongelli G, D’Alessandro R, Maddaloni V, Rau A, Sarkozy A, McKenna WJ, Ska-
etal muscle involvement in cardiomyopathies. J Cardiovasc Med (Hagerstown) 2013; 

43. Friedrich FW, Wilding BR, Reissmann C, Crocini C, Lang P, Charron P, Muller OJ, 
Wichter T, Madeira H, Arbustini E, Eschenhagen T, Mitchell CA, Isnard R, Carrier L. 
Evidence for FH1 as a novel disease gene for isolated hypertrophic cardiomyo-

44. Olive M, Goldfarb L, Moreno D, Lafort E, Dagadour J, Sambaghin N, 
myopathy: clinical, electrophysiological, radiological, neuropathological and 

45. Wilkson JD, Lowe AM, Salbert BA, Sleeper LA, Colan SD, Cox GF, Tothín VA, 
Connuck DM, Mcelhinney D, Lopina A, Charron P. Mitochondria SE. Outcomes in children with Noonan syn- 
drome and hypertrophic cardiomyopathy: a study from the Pediatric Cardiomyopat-
2776

ESC Guidelines


ESC Guidelines


Sigwart U. Non-surgical myocardial reduction for hypertrophic obstructive cardio-

Faber L, Welge D, Fassbender D, Schmidt HK, Horstkotte D, Seggewiss H. One-year follow-up of percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy in 312 patients: predictors of hemodynamic and clin-


Kuhn H, Lawrenz T, Lieder F, Leuner C, Strunk-Mueller C, Obergassel L, Bartelsmeier M, Stellbrink C. Survival after transcoronary ablation of septal hyper-


Ten Cate FJ, Soliman OI, Micheles M, Theuns DA, de Jong PL, Geleijnse MJ, Serruys PW. Long-term outcome of alcohol septal ablation in patients with ob-


Keane D, Hynes B, King G, Shields B, Brown A. Feasibility study of percutaneous transvenous endomyocardial cryoablation for the treatment of hypertrophic ob-


Shaib S, Rahman SM, Asmaa S, Jones S, McKenna W, Elliott P. The long-term sur-


Mickelsen S, Bathina M, Hsu P, Holmes J, Kusumoto FM. Doppler evaluation of the transvalvular endomyocardial cryoablation for the treatment of hypertrophic ob-


Takeda I, Sekine M, Matsushita H, Hosomi N, Nakamura T, Ohtsuki T, Yamawaki T, Matsumoto M. Two cases of cerebral embolism caused by atrial thrombi in mid-

Sato Y, Matsumoto N, Matsuo S, Yoda S, Tani S, Kasamaki Y, Takayana T, Kunimoto S, Sato S. Mid-ventricular obstructive hypertrophic cardiomyopathy associated with an apical aneurysm: evaluation of possible causes of aneurysm for-


Roising DR, Condit JR, Maron BJ, Kent KM, Leon MB, Benow RO, Lipson LC, Epstein SE. Verapamil therapy: a new approach to the pharmacologic treatment


